Synthesis of prenylated benzoquinones. by Ngcobo, N. Mlondi.
SYNTHESIS OF PRENYLATED BENZOQUINONES 
 
 




















School of Chemistry  
Faculty of Science and Agriculture  















Prof. F. R. van Heerden  
 
 
 ii  
ABSTRACT 
 
The research presented in this study demonstrates the critical role that organic synthesis plays 
in natural product chemistry. The biological activity demonstrated by 2-methyl-6-(3-methyl-2-
butenyl)benzo-1,4-quinone prompted an investigation into the synthesis of this compound. 
This natural product showed significant activity against Staphylococcus epidermidis. 
Therefore the aim of this study was to synthesise 2-methyl-6-(3-methyl-2-butenyl)benzo-1,4-
quinone and structural analogues.   
 
The regioselective synthetic route formulated for the synthesis of 2-methyl-6-(3-methyl-2-
butenyl)benzo-1,4-quinone involved five steps. Different strategies towards the synthesis of 
this compound were investigated. The regioselective C-alkylation step was proving to be the 
most challenging. The synthetic strategies investigated included carbon alkylation of a 
phenoxide, directed-o metallation, metal-halogen exchange and copper(II) Grignard-type 
metal halogen exchange.  
 
Problems were encountered with regioselectivity when carbon alkylation of a phenoxide was 
employed for the o-prenylation of o-cresol. The C-prenylated isomer was formed along with 
the O-prenylated isomer. When the reaction temperature was lowered, the yield of the desired 
C-prenylated isomer improved, whereas the yield of O-prenylated isomer declined. Although 
the reaction was performed under different conditions, the formation of the O-prenylated 
isomer could not be prevented.  
 
Therefore, another synthetic strategy was considered. The directed-o-metallation reaction was 
subsequently employed because of the associated regioselectivity. Unfortunately the desired 
product was not obtained when this method was employed. The reaction was attempted using 
different conditions, but the product could not be isolated.  
 
Since the directed-o metallation protocol did not yield the desired results, another method was 
considered. Therefore, a metal-halogen exchange reaction was employed. The metal-halogen 
exchange transformation was preceded by the preparation of the o-brominated precursor. 
 iii
Regioselectivity-related problems were initially encountered during the synthesis of the o-
brominated precursor. The o-brominated isomer was formed in a 1:1 ratio with the p-
brominated isomer. Further investigation led to a synthetic protocol that afforded the desired 
o-brominated isomer in a better yield. The metal-halogen exchange transformation was 
subsequently attempted, but the product was obtained in an unsatisfactory yield.  
 
Therefore, another method was employed in an effort to achieve regioselective C-alkylation 
with a better yield. Copper(II) Grignard-type metal-h logen exchange was successfully 
employed to achieve regioselective C-alkylation in good yield. The subsequent step was the 
deprotection, although problems were encountered, it was eventually achieved. The final step 
was the oxidation to obtain the desired compound, 2-methyl-6-(3-methyl-2-butenyl)benzo-1,4-
quinone. The same procedure was successfully applied in the synthesis of structural analogues 
2-isopentyl-6-methylbenzo-1,4-quinone, 2-(3,7-dimethylocta-2,6-dienyl)-6-methyl-1,4-
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General Introduction to Natural Product Chemistry     
         
1.1 Natural Product Chemistry in Drug Discovery 
 
Natural product chemistry has played, and continues to play, a major role in drug 
discovery. Drug discovery is a complex, interdisciplinary pursuit of chemistry, 
pharmacology, and clinical science, which has benefited humankind greatly over the last 
century.1 Chemists and biologists have attempted to explain the mystery of why so many 
compounds in nature have biological effects on humans and other species. The generally 
accepted explanation is based on the long-term co-evolution within biological 
communities; interacting organisms that evolved in close proximity to one another 
developed compounds that could influence biological processes of neighbouring species.2  
The secondary metabolites of diverse living organisms have potent biological activities and 
have afforded lead compounds in drug discovery for the treatment of cancer, microbial 
infections, inflammation, and hypercholesteremia and tissue rejection in organ 
transplantation. They have also provided several useful tools to pharmacologists and cell 
biologists.3 
 
Drugs of natural origin have been classified as original natural products, products derived 
semisynthetically from natural products or synthetic products based on natural product 
models.4 Although secondary metabolites are not produced by all organisms, the diversity 
of nature has translated into a wide variety of biological active compounds. The origins of 
these invaluable compounds are mainly plants, marine invertebrates and microbes. 
Significant strides have been made since the isolaton of the first commercial drug 
(morphine) and the use of microbial products as medicine (penicillin). 
 
Natural products and medicine have been closely linked through the use of traditional 
medicines and natural poisons.1 Approximately 60% of the world’s population largely 
relies on plants for medication.5 In developing countries such as South Africa, plants are 
still the most widely used and accessible source of primary medicine.  
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Clinical, pharmacological and chemical studies of traditional medicine derived from plants 
lead to the discovery of early medicinal compounds such as aspirin (1.1), digitoxin (1.2), 
morphine (1.3), quinine (1.4), and pilocarpine (1.5).1 Drug discovery was subsequently 
revolutionised by the commercialisation of synthetic penicillin, which was serendipitously 
discovered by Fleming in 1928 when he realized thata fungus of a Penicillium family 
produced a substance with great antimicrobial activity. Florey and Chain followed up on 








































The library of drugs derived from natural products has increased immensely from the first 
medicinal compounds. The pharmaceutical industry has benefited greatly from natural 
products. Natural products are well represented in the top 35 worldwide selling 
prescription drugs.1 Proudfoot also reported that 8 out of 20 of the small olecule drugs 
launched in year 2000 were derived from natural products or hormones.7  A study by 
Newman, Cragg, and Snader analyzing the number of natural products derived drugs 
present in the total drug launches from 1981 to 2002 demonstrated that natural products are 
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a significant source of new drugs.8 They also concluded that natural products were more 
prevalent in the anticancer and antihypertensive therapeutic areas.4,8  
 
Cancer is the leading cause of human death after cardiov scular diseases.6 Currently a 
substantial number of anticancer agents used are eith r natural or derived from natural 
products.9 The natural product-derived drugs paclitaxel (Taxol) (1.6) and vinblastine 
(Velban) (1.7) are two of the leading drugs in cancer treatment. Paclitaxel was originally 
isolated from the bark of Taxus brevifolia (yew tree), while vinblastine from the periwinkle 
plant of Madagascar (Catharanthus roseus).6 Curcumin (1.8) is another natural product 
drug involved in chemoprevention, a promising anticancer approach. Extracted from the 









































Although natural products are an unparalleled source of drugs, the advent of alternative, 
promising drug discovery methods has placed great pressure on natural product drug 
discovery programmes. In the last 10-15 years the int rest in natural products by major 
pharmaceutical companies has diminished in favour of new technologies such as 
combinatorial chemistry and rational drug design. Lately the interest in drug discovery 
from natural products has been greatly resuscitated by the failure of these technologies in 
delivering the promised number, novel and cheaper drug candidates. The recent 
developments have also demonstrated that combining natural products with some of the 
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new technologies furnishes a powerful tool for drug discovery. Therefore, modern natural 
products chemistry has re-emerged as a promising supplier of adequately sophisticated 
lead structures for drug discovery.3,11,12 Since only a small portion of the world’s 
biodiversity has been tested for biological activity,  can be assumed that natural products 
will continue to provide novel leads for new therapeutic agents.13  
 
1.2 Role of Total Synthesis in Natural Product Chemistry 
 
Total synthesis has played a pivotal role in natural p oduct chemistry. Natural products 
have furnished simple and complex molecules with biological activity, while total 
synthesis has been employed in the preparation of these medicinally important molecules. 
A clearly defined synthetic strategy for making a prticular natural product means that 
there is an everlasting source of that compound, even when the original natural source is 
extinct. The symbiosis between total synthesis and natural product chemistry has 
contributed greatly in the evolution and advancement of total synthesis. Novel natural 
products have coincided with the discovery of new synthetic methods.14    
 
Total synthesis has not only been used to conceive r ported natural products, but has also 
been used to develop new compounds with biological a tivity. It has played a critical role 
in the synthesis of structural derivatives of biologically active compounds, thus furnishing 
compounds with possible higher or lower biological activity. Some of the synthesised 
derivatives have afforded synergistic effects when administered with the original natural 
product. For example, the total synthesis of quinine (1.4) has been subsequently followed 
by the synthesis of various derivatives, including chloroquine (1.9), quinidine (1.10), 
pamaquine (1.11) and sontoquine (1.12). They all possess antimalarial activity like the 
parent compound, quinine (1.4). The combination of quinine (1.4) and pamaquine (1.11) 
rendered a powerful therapeutic tool. Quinine (1.4) on its own right affects the malaria 
parasite at the stage of its life cycle when it inhabits the bloodstream, whereas pamaquine 
(1.11) affects the parasite in the liver. The combination effectively clears an infection from 
both the liver and the blood.6  






















1.3 Aim of the Study 
 
The only South African Gunnera species is Gunnera perpensa L., known as uGobho in 
isiZulu and river pumpkin in English. Gunnera perpensa has been utilised by South 
African people in the treatment of menstrual pain, psoriasis and female infertility. The   
leaves have been used as a dressing for wounds.15    
 
The aims of the study: 
 The synthesis of 2-methyl-6-(3-methyl-2-butenyl)benzo-1,4-quinone isolated from 
leaves and stem of Gunnera perpensa. 
 The synthesis of structural derivatives. 
 
In the next chapter we will present a literature review on some the biological important 
naturally occurring 1,4-benzoquinones. We will also outline some of the synthetic 
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Biologically Active Quinones and Synthesis of Naturally Occurring 1,4-
Benzoquinones 
 
2.1 Biologically Active Naturally Occurring Quinones  
 
In this chapter we will discuss the importance of naturally occurring 1,4-benzoquinones. It 
will be illustrated by looking at the role they play in metabolic processes and their 
therapeutic value. The other objective is to briefly discuss the general synthesis of these 
compounds. There will also be a discussion on some f the most widely used synthetic 
strategies. 
 
Naturally occurring quinones are widespread in nature. They represent an important class 
of biological molecules possessing wide-ranging prope ties, and participate in various 
bioenergetic processes as important transport agents.1 Quinones are the largest group of 
natural pigments, but they play a relatively small role in natural colouring and their major 
contribution is in biological redox processes.2-4 Their importance and usefulness is not only 
limited to metabolic processes, but they also represent a clinically valuable entity for 
therapeutic agents with various applications.5   They are widely used as anticancer, 
antimicrobial, antitumour and antimalarial drugs as well as fungicides.  
 
Ubiquinones (Coenzymes Q) (2.1) are an example of quinones playing a critical role in 
biological redox processes. Ubiquinones are situated mainly in the mitochondria where 
they play a pivotal role in electron transport in the respiratory chain. Ubiquinones (CoQn) 
have different side chain lengths indicated by the number n after the name, which can 
range from 2 and 10 isoprene units. In a biological redox system, they can exist as either p-
benzoquinones (2.1) (ubiquinones, CoQn) or p-hydroquinones (2.2) (ubiquinonols, 
CoQnH2) (Scheme 2.1).
6-9 The structurally similar pastoquinones are also involved in 
electron transport. Plastoquinone-9 (2.3), which is found in the chloroplast of green plants, 
functions in the electron transport pathways in photosynthesis.10 The involvement of 
quinones in biological processes is not only limited o electron transfer, but they are also 
involved in oxidative phosphorylation.1  









































Scheme 2.1: Redox equilibrium of ubiquinones. 
 
2.2 Quinones with Anticancer Activity  
 
Quinones have demonstrated cytotoxic effects against various cancer cell lines. As a result, 
many quinone compounds have been screened for antitumour activity. The cytotoxic effect 
of quinones is predominantly due to their inhibition of DNA topoisomerase-II.5 In 
chemotherapy, the most significant property of quinones is their ability to undergo redox 
cycling to produce reactive oxygen species which can curtail tumour cells.  
 
Naturally occurring quinones are present in many drugs, such as the anthracyclines 
daunorubicin (2.4) and doxorubicin (2.5) and mitomycin (2.6), which are used clinically in 
solid cancer therapies.11 Although these quinones are structurally complex, even relatively 
simple benzoquinones exhibit significant biological activity; primin (2.7), for example, has 
demonstrated significant antitumor activity.12   Doxorubicin (2.4) is the most widely used 
anthracycline anticancer antibiotic. It was first isolated in 1967 from the fungus 
Streptomyces peucetius, it is active against several types of lymphoma, leukaemia, breast, 
ovary, bladder, stomach and thyroid gland cancer.13 
 
 






































Mitomycin (2.6) is another naturally occurring quinone that has received considerable 
attention because of its chemotherapeutic value. It is in the class of anticancer compounds 
that are termed archetypal bioreductive drugs. These anticancer compounds are inactive on 
their own, but upon metabolic reduction are transformed into cytotoxic species (Scheme 
2.2).10 Mitomycin is an alkylating agent, after metabolic reduction it forms crosslinks 
between DNA strands, thereby blocking DNA synthesis.13 The contribution made by 
quinones in cancer treatment encourages further study and exploration of quinones in order 



























Scheme 2.2: Metabolic reduction of mitomycin. 
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2.3 Quinones with Antimicrobial Activity  
 
There is a great demand for new antimicrobial agents wi h the ability to cure frequently 
occurring bacterial illnesses. Bacterial resistance to some of the antibiotics currently 
available, is another more prevalent reason for the search of novel antimicrobial agents.14 
The challenge became more apparent when it was discovered that, shortly after 
introduction of the various classes of antibiotics, new pathogenic strains emerged that were 
no longer susceptible to the antibiotics.13 Therefore, a concerted effort has been made to 
discover new antimicrobial agents to combat bacterial resistance. Quinones are amongst 
the large array of compounds that have been studied in order to discover new antimicrobial 
agents. 2,6-Dimethoxy-1,4-benzoquinone (2.8), 3,5-dimethoxy-2-phenyl-1,4-benzoquinone 
(2.9) and 3,5-dimethoxy-2-(4-formylphenyl)-1,4-benzoquinone (2.10) are some of the 

















2.4 Naturally Occurring Prenylated Benzoquinones 
Natural occurring quinones, especially prenylated bnzoquinones, play a critical role in 
several metabolic processes and possess significant biological activities. The ubiquinones 
(2.1) are a primary example of prenylated benzoquinones with biological importance. 
Besides their role in metabolic processes, its arsen l of biological activity includes 
termiticidal activity against Coptotermes formosanus.15  Prenylated benzoquinones are 
ubiquitous in nature, where they possess wide-ranging biological activities. Verapliquinone 
A and B (cis or trans isomer) (2.11), atrovirinone (2.12) and 2-(3-methylbut-2-enyl)-5-(2-
methylbut-3-en-2-yl)-1,4-benzoquinone (2.13) are some of the naturally occurring 
bioactive prenylated benzoquinones.16-18   






















   
2.5 Synthesis of Naturally Occurring Alkyl-1,4-benzoquinones 
 
Naturally occurring 1,4-benzoquinones have received considerable attention from synthetic 
chemists. The synthesis of these natural products has been stimulated by the associated 
biological activity. Several synthetic approaches have been formulated to permit the 
synthesis of these bioactive natural products. The structural diversity within this class of 
compounds has facilitated constant improvement and development of new synthetic routes. 
Because of the diverse structure, there is no general synthetic route towards natural 
occurring 1,4-benzoquinones.19,20   
 
The reported naturally occurring 1,4-benzoquinones are predominantly alkyl-1,4-
benzoquinones. Therefore, several synthetic routes that have been formulated are based on 
the requirements of simple alkyl-1,4-benzoquinones. Primin (2.7) is the most studied alkyl-
1,4-benzoquinone, this can be attributed to its biological properties. Consequently, several 
synthetic routes have been developed based on the synthe is of primin (2.7).    The general 
synthesis of primin (2.7) normally involves two critical steps. The C-alkylation of the 
phenol 2.14 and the oxidation of the alkylated phenol 2.15 to the product, primin (2.7)19 
(Scheme 2.3).  









2.14 2.15 2.7  
 
Scheme 2.3: Outline of the general synthetic route towards primin 
 
Besides, primin (2.7), there are several simple alkyl-1,4-benzoquinones that have been 
synthesised. Variable synthetic strategies have been employed in the synthesis of these 
natural products. The C-alkylation, specifically ortho-alkylation, of the corresponding 
phenol has proven to be a challenging task. Consequently, there has been a concerted effort 
to improve conventional methods and also discover simple and more efficient methods.  
Directed ortho-metallation (DoM), Claisen rearrangement and metal-halogen exchange 
reactions are some of the synthetic strategies that have received considerable attention.  
 
2.5.1 Directed ortho-Metallation (DoM) 
 
Directed ortho-metallation (DoM) is one of the strategies employed in the regiospecific 
preparation of substituted aromatic compounds. The DoM reaction involves deprotonation 
by a strong base at the ortho position of an aromatic compound containing a directed 
metallation group (DMG) (2.16). Alkyllithium reagents are normally used as the base to 
furnish an ortho-lithiated product (2.17) which subsequently reacts with electrophilic 





2.16 2.17 2.18  
 
Scheme 2.4: Ortho-alkylation using simple DoM reaction. 
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Although DoM has been successfully employed in the synthesis of naturally occurring 1,4-
benzoquinones, it has also demonstrated significant limitations.12 The success of a DoM 
reaction largely depends on the aromatic compound, base and DMG used. Limitations have 
been experienced during deprotonation of aromatic compounds with two or more oxygen 
substituents, due to proton transfer from the ortho groups (DMG) such as –OBn or -
OMOM that quenches the aryl anion. Although acetals and carbamate can be employed as 
DMGs to avoid this complication, they also have their own limitations. The carbamate has 
the ability to migrate to the ortho lithiated aryl carbon atom at temperatures greater than 60 
oC, generating the corresponding salicylicamide.25  
 
The strong alkyllithium bases that are preferred for D M reactions, are also not without 
limitations. They form aggregates of defined structures in organic solvents.  They normally 
form hexamers in hydrocarbon solvents and tetramers and dimers in Lewis basic solvents. 
The formation of the alkyllithium aggregates significantly decreases the basicity.  This 
limitation has been addressed by the use of bidentate ligands, such as TMEDA. It breaks 
down the aggregates, producing monomers and dimers in solution and consequently 
increasing basicity.22 This promotes formation of the lithiated species, which have also 
demonstrated poor reactivity, to achieve coupling they have been activated by formation of 
cuprate intermediates (Scheme 2.5).26 Although the DoM reaction encompasses numerous 
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2.5.2 Claisen Rearrangement  
 
The Claisen rearrangement was first reported almost a century ago, by Ludwig Claisen.27 
Since its discovery it has been regarded as a useful tool in synthetic organic chemistry.  It 
was the first sigmatropic rearrangement to be discovered. It occurs when an aryl allyl ether 
(2.19) is heated without solvent and an ortho-allyl phenol (2.20) results (Scheme 2.6).28 








Scheme 2.6: Mechanism of a [3,3] sigmatropic rearrangement. 
 
The usefulness of this reaction has prompted substantial development and improvement of 
the constituting parameters. Through technology the efficiency of the Claisen 
rearrangement has been greatly improved by microwave irradiation. The long reaction 
times associated with conventional Claisen rearrangement conditions are significantly 
reduced under microwave conditions.29 The transformation of the Claisen rearrangement 
from a simple thermal process into a microwave-assisted reaction has enhanced its 
application. Consequently, microwave-assisted aromatic Claisen rearrangement has 
emerged as a key step in the synthesis of various naturally occurring 1,4-benzoquinones. It 
has demonstrated simplicity and versatility during the synthesis of these natural products. 
The versatility of microwave-assisted aromatic Claisen rearrangement has been confirmed 
by its successful combination with the Mitsunobu reaction in a one-pot operation. The 
Mitsunobu reaction is one of the methods that are employed in the synthesis of aryl allyl 
ethers (2.21), which are precursors for the Claisen rearrangement (Scheme 2.7). The 
Mitsunobu reaction-Claisen rearrangement protocol has become a preferred strategy in the 
synthesis of naturally occurring 1,4-benzoquinones. It was successfully employed by 
McErlean and Moody in the synthesis of two naturally occurring alkyl-1,4-benzoquinones, 
raponone (2.22) and N-(3-carboxylpropyl)-5-amino-2-hydroxy-3-tridecyl-1,4-
benzoquinone (2.23).20  
 




















220 oC, 30 min
 
  
R1, R3 = H 
R2 = CH3 
 
Scheme 2.7: Synthesis of ortho-alkylated phenyls using the  Mitsunobu reaction- 
          Claisen rearrangement protocol.  



















2.5.3 Metal-Halogen Exchange (MHE) 
 
The reaction of organometallic compounds with organic halides is an extensively studied 
reaction in organic chemistry. Metal-halogen exchange reactions can be employed during 
the synthesis of ortho-alkylated aromatic species. It has received considerable attention in 
the synthesis of alkyl-1,4-benzoquinones, because it provides high control of 
regioselectivity. The first step in the metal-halogen exchange reaction is normally the 
ortho-halogenation, followed by protection with a corresponding protecting group. The 
next step is the displacement of the halogen with an appropriate metal. The organometallic 
species is subsequently reacted with an electrophile. The resulting compound is then 
deprotected to afford an ortho-alkylated phenol (Scheme 2.8). The efficiency and 
effectiveness of this reaction mostly depends on the halogen species employed. For 
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Scheme 2.8: Synthesis of ortho-alkylated phenol using a metal-halogen exchange  
          reaction.                        
 
In this chapter the importance of natural occurring 1,4-benzoquinones has been 
demonstrated by the role they play in chemotherapy. It has also affirmed the critical and 
challenging role that organic synthesis plays in natural product chemistry. The synthesis of 
alkyl-1,4-benzoquinones was also introduced, with a brief discussion on the challenging 
ortho-alkylation process.  
 
Therefore, some of the most employed synthetic strategies in the manifestation of this 
process were outlined. The subsequent chapter will discuss the synthesis of 5-(3-methyl-2-
butenyl)-2-methylbenzo-1,4-quinone (2.24) and associated structural derivatives 2.25 - 
2.28. The discussion will be based on the synthetic strategies and various techniques that 
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Synthesis of a Naturally Occurring 1,4-Benzoquinone and Structural 
Analogues 
 
3.1 Synthetic Approach  
 
This chapter will discuss the synthesis of 2-methyl-6-(3-methyl-2-butenyl)benzo-1,4-
quinone (2.24) and its structural analogues 2.25-2.28.  2-Methyl-6-(3-methyl-2-
butenyl)benzo-1,4-quinone (2.24) is a 1,4-benzoquinone derivative isolated from the 
dichloromethane extract of the leaves and stem of Gunnera perpensa. It showed significant 
activity against Staphylococcus epidermidis.1 S. epidermidis are gram-positive pathogenic 
bacteria that occur in microscopic clusters resembling grapes and are common in medical 


















As highlighted in Chapter 1, Section 1.3, the aim of this study was the synthesis of 2-
methyl-6-(3-methyl-2-butenyl)benzo-1,4-quinone (2.24) and its structural analogues 2.25-
2.28. The antimicrobial activity of 2.24 prompted us to synthesise this compound and the 
related analogues. Furthermore, the development of versatile and flexible routes towards 
prenylated quinones is a matter of interest for synthetic chemists, due to the role they play 
in biological processes and their pharmacological properties.3-5  The objective was to 
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prepare 2.24 and a number of derivatives to investigate the contribution made by different 
substituents on the biological activity of the compounds.  Consequently, analogues with 
extended side chains and saturated side chains were synthesised in order to investigate the 
effect of the side chain on the associated biological a tivity. A retrosynthesis analysis of 
2.24 suggested that 2.24 might be obtained from a prenylated phenol derivative, which can 





2.24 3.2 3.1  
 
Scheme 3.1: Retrosynthetic analysis of parent compound 2.24.  
 
The proposed analogues 2.25-2.28 are structurally similar to the parent compound 2.24. 
Therefore, it was envisaged that the synthetic strategy employed in the synthesis of 2.24 
could also be employed in the preparation of analogues 2.25-2.28. It was critical to develop 
a reliable synthetic approach characterised by consistency, wide applicability and mild 
conditions.  The first synthetic approach to 2.24 involved carbon alkylation of a phenoxide.  
 
3.2 Carbon Alkylation of a Phenoxide 
 
A retrosynthetic analysis suggested that carbon alkylation of a phenoxide could be 
employed in the synthesis of 2-methyl-6-(3-methyl-2-butenyl)benzo-1,4-quinone (2.24). 
The first step in the preparation of the parent 2.24 was ortho-prenylation of o-cresol (3.1), 
forming the ortho-prenylated phenol (3.2). This step can be achieved through carbon 
alkylation of a phenoxide. Phenoxide carbon-alkylation has been widely employed in the 
preparation of ortho-prenylated phenols.6 The synthesis of 3.2 using carbon alkylation of a 
phenoxide has been reported by Yamada et l. The results obtained by Yamada et al. were 
motivating since the desired compound 3.2 was obtained in 76% yield.7,8  
 
However, it has also been reported that ortho-prenylation by carbon alkylation of the 
phenoxide is associated with low yields.6 The low yields have been attributed to the 
occurrence of side reactions. The competing reactions are normally para-carbon 
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prenylation, bis-prenylation and oxygen-prenylation. This is because the phenoxide ion is 
capable of coupling at the oxygen or at the ortho and para-positions on the ring (Scheme 
3.2). Therefore, blocking of the para-position is one of the methods that have been 
















Scheme 3.3: ortho-Prenylation of a phenol with a blocked para-position. 
 
In this investigation, the first proposed synthetic approach to 3.2 did not include the 
blocking of the para-position, since a good yield was reported by Yamada et al. without 
blocking the para-position.7,8,12 The first step in the proposed synthetic route towards 2.24 
was thus C-alkylation using the Yamada et al.7,8 protocol. The second step was the 












Scheme 3.4: Proposed synthesis of 2.24, after Yamada et al.7,8 
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Therefore, metallic sodium was added slowly to a solution of diethyl ether and o-cresol 
(3.1). The resulting mixture was stirred for 1 h, the pr nyl bromide was added slowly and 
the mixture was subsequently refluxed for 10 h. Two pr ducts were isolated and identified 
as 3.2 (39%) and 3.3 (36%). The 1H NMR assignments for 3.2 correlated well with those 
reported by Yamada t al.7 The 1H NMR spectrum (Fig. 3.1) of 3.2 was characterised by 
the broad singlet of a phenolic proton at δH 5.11; the presence of the phenolic proton was 
also confirmed by a broad IR absorption band at 3564 cm-1. The observed signals in the 
aromatic region of the 1H NMR spectrum of 3.2 also confirmed ortho-prenylation; the 
expected two doublet signals of H-3 and H-5 were observed at δH 6.97 (d, J = 7.4 Hz) and 
δH 6.93 (d, J = 7.2 Hz), and a triplet for H-4 was observed at δH 6.74 (t, J = 7.4 Hz). On the 
other hand, the O-prenylated product 3.3 was indicated by the absence of a signal due to 
the phenolic proton in the 1H NMR spectrum (Fig. 3.2). The downfield shift of the 
methylene protons 2H-1’ was also diagnostic of O-prenylation. Due to oxygen-associated 
deshielding, the signal was observed at δH 4.51 in 3.3, whereas in 3.2 it was observed at δH 



















Although the desired 3.2 was obtained, we were not satisfied with the associated yields. 
The reaction was repeated several times in an effort to reproduced the results obtained by 
Yamada et al.7  The highest yields that were obtained under these conditions were 40% for 
the desired product 3.2 along with the side product 3.3 at 32%. Consequently, we decided 
to explore other reaction conditions. Kornblum et al. reported that solvation plays a 
significant role in the carbon alkylation of phenoxide ions.13,14 According to Kornblum et 
al., the solvent used can be the deciding factor on whether C-alkylation or O-alkylation is 
observed.13,14 Therefore, the solvent was changed; THF was used instead of diethyl ether. 
Unfortunately, the O-alkylated side product 3.3 was obtained as the major product, there 
was only a trace of the desired product 3.2.
















Figure 3.2: 1H NMR spectrum (CDCl3, 400 MHz) of 3.3. 
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Since better results were obtained when using diethyl t er, it was decided to retain this 
solvent and manipulate other reaction conditions. The effect of heat was investigated by 
lowering the temperature. Therefore, the reaction was repeated with the initial temperature 
at 0 oC. The temperature was subsequently allowed to rise to room temperature and the 
reaction was stirred overnight. When the reaction was analysed, the desired product 3.2









Scheme 3.5: ortho-Prenylation following the Yamada et al. protocol at 0 oC.7,8   
 
Since these results were consistent and reproducible, it suggested that ortho-prenylation of 
ortho-cresol is favoured by lower temperatures. The results obtained indicated that 
performing the reaction under these conditions promotes the formation of the ortho-
carbanion 3.7, while suppressing the emergence of the phenoxide ion 3.6 and para-
carbanion 3.8 (Scheme 3.6). We then decided to explore temperatur s below 0 oC, 






3.6 3.7 3.8  
 
Scheme 3.6: Intermediate carbanions that could be formed from -cresol (3.1). 
 
Since the formation of the O-alkylated product 3.3 could not be prevented, alternative 
methods were considered. Our decision was  vindicated by the results reported by Shubina 
et al.15, which came to our attention while still we were investigating the Yamada7 
protocol. Shubina et al.15 performed C-alkylation of 3.9 with geranyl bromide using 
Yamada’s et al.7 protocol; the desired product 3.10 was obtained in low yields. When the 
reaction conditions were changed, the yield of the product did not increase. Instead 3.11 
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and 3.12 emerged as products (Scheme 3.7).16 Therefore, it was suspected that similar 
challenges would be encountered during the synthesis of analogues. Consequently, 
























   
 
Scheme 3.7: Attempted synthesis of compound 3.10 by Shubina et al. using the Yamada  
          protocol. 
 
 
3.3 Directed ortho-Metallation (DoM) 
 
During the search for a new synthetic strategy, we targeted a synthetic approach that is 
characterised by regioselectivity and wide application. Subsequently, a directed ortho-
metallation (DoM) reaction was considered because of the associated regioselectivity.  
Although the DoM transformation provided regiospecificity, it also increased the number 
of step involved in the proposed synthetic sequence (S heme 3.8). The first step was the 
introduction of the directed metallation group (DMG). We decided to employ a methoxy (-
OCH3) group as the DMG since it has been widely used in DoM reactions. Amongst all 
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substrates available for investigation under the DoM protocol, anisole has been the 
preferred candidate.17-21   Therefore, the first step was the methylation of o-cresol (3.1) and 
this transformation was first attempted with NaH and MeI. The product 3.13 was identified 
by the presence of the OCH3 signal at δH 3.81 (3H, s) in the 
1H NMR spectrum. The 
presence of the OCH3 was also supported by the signal at δC 63.9 (OCH3) in the 
13C NMR 
spectrum.   The product 3.13 was unfortunately obtained in an unsatisfactory yield of 48%. 
Therefore, an alternative method was considered and we decided to employ dimethyl 
sulfate (Me2SO4) as the methylating electrophile and Na2CO3 as the base to form the 

















Scheme 3.8: Proposed synthetic sequence for 2.24 based on the  DoM protocol. 
 
The successful synthesis of 3.13 was subsequently followed by the attempted synthesis of 
3.15. Although the transformation from 3.13 to 3.15 was going to be achieved through a 
single reaction, it was envisaged to be a three-step process. The first step is the 
coordination of n-butyllithium dimer to the electron-rich anisole (3.13), followed by metal-
proton exchange to give 3.14 by a simple DoM reaction. The last step is the coupling of the 
prenyl bromide.17,18,23,24 The reaction was performed under anhydrous conditions n a N2 
atmosphere, since the presence of water would prevent the formation of the aryl 
organolithium product 3.14. The first step was the deprotonation of compound 3.13 using 
the strong base n-BuLi (1 eq) to form 3.14. This reaction was performed in dry diethyl 
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ether at -78 oC, it was subsequently followed by the in situ ortho-prenylation using the 
electrophilic prenyl bromide. Unfortunately, the desir d product was not obtained.  
 
The reaction was repeated several times, but product 3.15 was not obtained.  Different 
amounts of n-BuLi were employed, but to no avail. Since there was uncertainty on whether 
it was the deprotonation step or the coupling step that was not working, limitations 
associated with the DoM reaction were considered. Some of the limitations were 
highlighted in the previous Chapter. One of the problems that could prevent the formation 
of compound 3.14 is the ability of organolithium reagents to form aggregates in organic 
solvents. As mentioned in Chapter Two, alkyllithium reagents have a tendency to form 
electron-deficient tetrameric aggregates (3.17) in Lewis base solvents such as diethyl ether. 
The formation of these aggregates (3.17) greatly decreases the basicity of alkyllithium 
species thus suppressing the metal-proton exchange process. In addition, a study of the 
structure of 2-lithioanisole indicated that the possible internal coordination between the 
lithium and the oxygen from the methoxy group highly reduces the nucleophilicity of 
anisole (3.16), thus making it almost unreactive to electrophiles.25 Since a methoxy group 
was employed as a DMG, it was suspected that limitations relating to aggregate formation 
could be preventing the formation of the product 3.15.    
 
The formation of aggregates can be prevented by the use of bidentate ligands, such as 
TMEDA. It breaks down the aggregates, producing monomers and dimers in solution and 
consequently increasing basicity (Scheme 3.9). This subsequently increases the rate and 
the extent of metallation.20,21,24 Therefore, we decided to repeat the reaction in the presence 
of TMEDA (1 eq.). Unfortunately, the use of TMEDA did not yield better results, as the 
coupled product was still not observed. Different amounts of TMEDA were employed, but 
the results were still the same, no product.  Because the nature of the resulting aggregates 
is determined by the solvent employed, we decided to change the solvent from diethyl 
ether to THF. This strategy also did not yield the desired results.  
  













































Scheme 3.9: Dissociation of the tetrameric organolithium with TMEDA. 
 
Since the employed strategies did not yield positive results, alternative methods were 
considered. As it was mentioned in the previous Chapter, sometimes, in order to attain 
coupling, the lithiated species need be activated. Subsequently, a method by Bouzbouz and 
Kirschleger was adopted, where they activated the li iated species by the formation of a 
cuprate intermediate.9,26 The reaction was repeated using similar conditions to those 
reported by Bouzbouz and Kirschleger, but instead of sec-BuLi, n-BuLi was used (Scheme 
2.5).9 Unfortunately, despite several attempts, product 3.15was not obtained.  
 
Although positive results were not obtained with the DoM protocol, a different DMG was 
considered, since some of the complications that were encountered could be associated 
with the use of methoxy as DMG. Guided by the results reported by Brondani et al., THP 
was employed as the DMG.27 These authors employed a DoM protocol to obtain 3.19 from 
3.18 in a yield of 70% (Scheme 3.10).6,27,28  
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Scheme 3.10: Brondani’s synthesis of 3.19 from 3.18 using the DoM strategy.27 
 
The first step was the protection of the phenolic hydroxy group using dihydropyran in the 
presence of a catalytic amount of anhydrous p-toluenesulfonic acid (p-TsOH) (Scheme 
3.11). The product 3.20 was successfully obtained in a yield of 72%. The 1H NMR 
spectroscopic analysis confirmed the formation of 3.20 by the absence of the broad singlet 
due to the phenolic proton. The expected downfield 1H triplet signal due to the anomeric 
proton (H-1’) was also observed at δH 5.45 (t, J = 3.1 Hz,), it integrated for one proton. The 
signals due to the THP carbon atoms were also observed in the 13C NMR at δC 96.1 (C-1’), 
62.0 (C-5’), 30.6 (C-2’), 25.3 (C-4’), 19.0 (C-3’). The HRMS (ESI+) analysis confirmed 
the molecular formula of 3.20 ([M+Na]+ obsd. 215.1048, calc. for C12H16O2Na 215.1047). 
The subsequent step was the DoM protocol, where n-BuLi was employed as the base. 
Unfortunately, despite several attempts, the desired product could not be isolated. The 
reaction conditions were subsequently manipulated by adding TMEDA and CuI, 
















Scheme 3.11: The proposed synthetic strategy to 3.21.27  
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Due to the discouraging results that were recorded with all attempted coupling using the 
DoM protocol, the use of this protocol was suspended. Therefore, a different synthetic 
route towards 2-methyl-6-(3-methyl-2-butenyl)benzo-1,4 quinone (2.24) was formulated.    
 
3.4 Metal-Halogen Exchange (MHE) Mediated Transformation. 
 
Guided by the requirement for a synthetic approach that permitted C-alkylation without the 
formation of regioisomers, metal-halogen exchange became a plausible option. In a MHE-
mediated C-alkylation, the issue of regiocontrol is reassigned to the preparation of the 
ortho-halogenated species.6  Terashima et al. successfully employed MHE mediated 
transformation to achieve regioselective C-alkylation.29 The reported successful synthesis 
of prenylated aromatic compounds by Odejinmi and Wiemer further confirmed MHE-
mediated transformation as a pragmatic option.30  Therefore, a synthetic route based on 






















Scheme 3.12: Proposed MHE-based synthesis of 2.24 
 
The first step was the synthesis of the o-brominated 3.22. There are a variety of methods 
that have been employed to achieve bromination of phenols.31-36 The most prominent one 
has been the treatment with bromine in different solvents, but the formation of a mixture of 
regioisomers sometimes emerge; thus decreasing the yield of the desired product.32 
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Therefore, this method could not be employed in the synthesis of 3.22, since regioselective 
o-bromination was the target. Carreño et al. reported that regioselective o-bromination of 
o-cresol (3.1) can be achieved with N-bromosuccinimide (NBS) in CH2Cl2.
32
 
Consequently, this synthetic sequence was employed in the synthesis of 3.22, unfortunately 
the results obtained did not correspond with the results reported by Carreño et al.32 The 
desired product 3.22 was obtained in an unsatisfactory yield along with the para-
brominated regioisomer 3.24 in almost the same amount (Scheme 3.13). The two products 
were identified and differentiated by 1H NMR analysis. As expected, the 1H NMR 
spectrum of 3.22 was characterised by the presence of the triplet at δH 6.69 (1H, t, J = 7.7 














Scheme 3.13: Bromination of o-cresol (3.1) using NBS in CH2Cl2, after Carreño et al.
32 
 
Since the formation of the para-regioisomer 3.24 could not be prevented with this 
approach, a different synthetic route was considered. Subsequently, a method reported by 
Fugisaki et al. came to our attention.37,38 A phenol was treated with NBS in the presence of  
a secondary amine (i-Pr2NH) at room temperature in CH2Cl2 and afforded the o-
brominated regioisomer as a major product. The para-brominated regioisomer and 
polybrominated species were recorded in very low yields. There are also earlier reports on 
the application of amines during o-bromination, but the method by Fugisaki et al. was 
preferred since it uses mild conditions. Therefore, o-bromination of o-cresol was 
performed using these conditions and the desired 3.22 was obtained as a major product 
with a yield of 64%. The para-brominated regioisomer 3.24 was isolated in a yield of 23% 
(Scheme 3.14). When the temperature was decreased to 0 oC, the desired product 3.22 was 
obtained in a better yield of 73%.  
 
 





Scheme 3.14: Bromination of o-cresol (3.1) using NBS in the presence of i-Pr2NH. 
 
It was also interesting to note that the presence of undissolved NBS in the reaction mixture 
promoted the formation of the para-regioisomer, even in the presence of i-Pr2NH. This 
indicated that the reaction between solid NBS and o-cresol superseded the reaction that 
should first take place between i-Pr2NH and NBS. In order to promote o-bromination, the 
N-bromoamine (i-Pr2NBr) should be generated, which first forms a strong hydrogen bond 
with o-cresol (3.1) to afford bromination at the ortho-position. Therefore, in order to 
promote the formation the i-Pr2NBr, NBS should be completely dissolved in CH2 l2 
before mixing it with o-cresol (3.1) and i-Pr2NH.  
 
The successful preparation of 2-bromo-6-methylphenol (3.22) was subsequently followed 
by the synthesis of 2-bromo-6-methylanisole (3.23). The method that was used to 
synthesise 2-methylanisole (3.13) was also employed in the synthesis of 3.23.22 The 
product 3.23 was obtained in a good yield of 95%.  The presence of a signal at δH 3.85 
(3H, s) and δC 60.1 in the 
1H and 13C NMR spectra confirmed the presence of the methoxy 
group. The HRMS (ESI+) analysis also confirmed the molecular formula of 3.23 (obsd. m/z 
200.9841, calc. for C8H10O
77Br m/z 200.9842). 
 
The successful synthesis of the two precursors 3.22 and 3.23 created the platform for the 
exploration of the MHE-facilitated transformation. The reaction was first attempted 
without the addition of CuI, but TMEDA was added to prevent the formation of aggregates 
(Scheme 3.9). The reaction was performed at various temperatures, while the solvent, 
diethyl ether, and n-BuLi were fixed. When the reaction was performed at temperatures 
between -20 oC and -78 oC, there was no product observed, even when CuI was added.29 
The product 3.15 was only observed at temperatures between 0 oC and -10 oC, but in low 
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reaction was performed at 0 oC (Scheme 3.15). The addition of CuI unfortunately did not 
improve the yield. The structure of 3.15 was elucidated using NMR spectroscopy. The 
presence of a signal at δH 3.35 (2H, d, J = 7.2 Hz) in the 
1H NMR spectrum indicated 
successful coupling (Fig. 3.3). The methylene protons (2H-1’) signal which was recorded 
at  δH 3.35 had the expected upfield shift from δH 4.02 that was observed for the starting 
material, prenyl bromide. The molecular formula of 3.15 was also confirmed by HRMS 




























Figure 3.3: 1H NMR spectrum (CDCl3, 400 MHz) of 3.15. 
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Although MHE-mediated transformation delivered the correct regioselectivity, the yield 
obtained was very discouraging. While attempting to repeat the reaction using a benzylated 
precursor as reported by Odejinmi and Wiemer, the results recorded by Scheepers t al. 
were discouraging.30,39  Scheepers et al. reported that the attempted MHE reaction using a 
benzylated precursor was unsuccessful. Although Scheepers et al. subsequently 
synthesised 3.26 from a methylated precursor (3.25), the reported yield was low (Scheme 
3.16).39 Therefore, it became apparent that a different synthetic sequence had to be 













Scheme 3.16: Synthesis of 3.26 using a MHE-mediated transformation as reported by  
  Scheepers et al.39 
 
Unfortunately, when our MHE reaction was performed, Klein et al. had not  yet published 
their work on factors influencing prenylation of an romatic organolithium compound. 
Klein et al. established that the formation of aggregates persist even in the presence of 
TMEDA. They also discovered that alteration of the sequence in which the reactants are 
added significantly improves the yield. Although the reaction was performed under strictly 
anhydrous conditions, they decided that to test the role that is played by traces of water that 
could be present. Therefore, the sequence of adding reactants was reversed; excess n-BuLi 
and TMEDA were initially combined with diethyl ether, in order to quench traces of water 
and to prevent protonation of the organolithium intermediate that forms through metal-
halogen exchange. Consequently, the yields of the reaction improved from a variable 5-
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3.5 Copper (II)-Mediated Regioselective Alkylation  
 
Although the o-alkylation step was proving to be challenging, the work by Burns et al. was 
very encouraging.41 These authors achieved o-alkylation of anisole with 1,3-
dibromopropane in 70-80% yields. o-Bromoanisole (3.27) was first reacted with 
magnesium to form a Grignard reagent, (2-methoxyphenyl)magnesium bromide (3.28), 
which was subsequently reacted with 1,3-dibromopropane in the presence of catalytic 













Scheme 3.17: Burns et al.  regioselective o-alkylation.41 
 
It was also interesting to note that Liet al. successfully employed the Burns copper-
mediated transformation in order to synthesise 3.29 in a yield of 71%.42,43  These results 
demonstrated a significant improvement when compared with the results by Scheepers et 
al. performing the same transformation using a lithium-halogen exchange reaction 
(Scheme 3.15).39 Consequently, a synthetic route towards 3.15 was formulated based on 































Scheme 3.18: Proposed synthetic route towards 2.24 based on Burns et al. protocol.41 
 
A model reaction was formulated in order to verify the prenyl bromide coupling using 
Burns’s protocol (Scheme 3.15). o-Bromoanisole (3.27) was reacted with magnesium in 
order to form a Grignard-type reagent (3.28) (Scheme 3.16). The resulting Grignard 
reagent (3.28) was cannulated into a solution of Li2CuCl4 and prenyl bromide in order to 
achieve transmetallation. Subsequent coupling lead to the product 3.30 which was obtained 
in a yield of 81% (Scheme 3.19).41,42  
 













Scheme 3.19: Synthesis of model product 3.30.  
 
Successful coupling was first indicated by a signal at δH 3.34 (2H, d, J = 7.7 Hz) due to the 
methylene protons (2H-1’) observed in the 1H NMR spectrum of 3.30. The downfield 
aromatic region integrated for four protons. The molecular formula of 3.30 was also 
confirmed by HRMS (ESI+) analysis ([M+H]+ obsd. m/z 177.1276, calc. for C12H17O 
177.1275). The successful synthesis of 3.30 was subsequently followed by the synthesis of 
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3.15. The synthesised 2-bromo-6-methylanisole (3.23) was reacted with Mg to form 3.31 
and was subsequently coupled with prenyl bromide. The product 3.15 was obtained with a 
reproducible yield of 71% (Scheme 3.20), which was much better than the 12% yield that 
was obtained by the lithium MHE-mediated transformation. 















Scheme 3.20: Synthesis of 3.15 using Burns’ protocol.41 
 
The subsequent step was the deprotection of the aryl methyl ether 3.15. Aryl methyl ethers 
can tolerate a variety of reagents and experimental conditions, but their high stability 
creates a problem when removing the protecting group.44 Harsh conditions such as strong 
acids or bases, alkali metals, or oxidising reagents and reducing reagents are generally 
employed in the cleavage of methyl ethers.44-51 These conditions often result in undesirable 
products and low reaction yields. Therefore, there has been a great desire amongst 
chemists for the development of a synthetic protocol characterised by chemoselectivity and 
regioselectivity. The use of Lewis acids such as  BBr3 as a demethylation reagent has been 
prevalent because of the associated relatively mildconditions, but this method has been 
characterised by long reaction times.47  
 
Consequently Zou et al. developed a demethylation protocol characterised by relative mild 
reaction conditions and shorter reaction times.44 Zou et al. employed iodocyclohexane in 
DMF under reflux to achieve the demethylation of 5,7-dimethoxy-4-methylphthalide 
(3.32) over 14 h in 91% yield. 52 The results obtained by these authors demonstrated 
significant improvement when compared with the results obtained by Canonica et al. while 
performing the same transformation using different synthetic protocols (Scheme 3.21).44,52  
 










Method A: BBr3, rt, 8 d, 70% yield. 
Method B: 57% HI, anhyd P, Ac2O, reflux, 12 h, 49% yield. 
 
Scheme 3.21: Canonica et al. approach to the demethylation of 3.32.52 
 
Therefore, Zou’s approach was adopted for the demethylation of 3.15.  In order to probe 
this protocol, a model reaction was performed. Demethylaion of 2-bromo-6-methylanisole 
(3.23) was undertaken as the model reaction using the Zou  conditions.44 The demethylated 
product 3.22 was successfully obtained in a yield of 86% (Scheme 3.22). Successful 
demethylation was confirmed by the presence of a bro d singlet at δH 5.54 which coincided 
with the disappearence of the signal due to OCH3 in the 
1H NMR spectrum of 3.22.  
Therefore, the same procedure was employed in the demethylation of 3.15. The desired 
product was not obtained, although the reaction was repeated several times. The product 














Scheme 3.22: Demethylation of 2-bromo-6-methylanisole (3.23). 
 
Since the desired product 3.2 was not obtained, alternative methods were considered in 
order to achieve the cleavage of the aryl methyl ether 3.15. A synthetic approach by Fang 
et al. was considered. The cleavage of the aryl methyl et er was performed by Fang et al. 
using LiCl in DMF under microwave irradiation.45 Using microwave irradiation 
significantly improved the reaction efficiency. Fang’s approach was subsequently 
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employed in an attempt to demethylate 3.15. Unfortunately product 3.2 was not formed. 
Prolonging the reaction time and also changing the microwave parameters such as 
temperature did not yield the required results. 
  
The search for a demethylation procedure led us to a paper by Shindo et al.53 These authors 
reported successful demethylation of aryl methyl ethers, using lithium and ethylenediamine 
in THF under mild conditions.53,54 Although there is no generally accepted mechanism for 
this reaction, the yields obtained were very encouraging.53 As a result Shindo’s method 
was the subsequent synthetic strategy that was employed in order to obtain demethylation 















A solution of lithium (5 eq) and ethylenediamine (7 eq) in THF under N2 at 0 
oC was added 
3.15 (1 eq). The addition of the reagents was preceded by egassing in order to remove 
traces of oxygen, since oxygen was reported to prevent formation of the desired product.53  
This has also been regarded as an indication that the demethylation occurs by an electron 
transfer reaction mechanism. The reaction mixture was allowed to stir at 0 oC for 2 h to 
give a deep blue reaction mixture. The reaction products were purified by silica column 
chromatography to give 2-methyl-6-(3-methyl-2-butenyl)phenol (3.2) in 84% yield. The 
product 3.2 was confirmed by the presence of a broad singlet in the 1H NMR spectrum 
(Fig. 3.1) at δH 5.11 due to the phenolic proton. The observed IR absorption band at 3564 
cm-1 also indicated the presence of OH functionality.  The molecular formula of 3.2 was 
also confirmed by HRMS (ESI-) analysis ([M-H] - obsd. m/z 175.1118, calc. for  C12H15O 
175.1123).  
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The successful synthesis of 3.2 was subsequently followed by oxidation to afford the arget 
compound 2.24 (Scheme 3.16). Fremy’s salt (KSO3)2NO was used as the oxidant to obtain 
the product in a yield of 49%.4,55 The moderate yield obtained prompted a search for 
another method that would afford better yields. The cobalt-Schiff base complex, [bis-
(salicylidene)ethylenediamine]cobalt (salcomine) (3.34), prevailed as the oxidant that 
would probably give better yields.56-64 Therefore salcomine [(salen)Co] (3.34) was 























Scheme 3.24: Synthesis of salcomine (3.34). 
 
The first step was the synthesis of the Schiff base ligand, N,N’-ethylene-bis-
salicylidenimine (3.33). The product 3.33 was obtained in a yield of 82%. The Schiff base 
ligand 3.33 was subsequently reacted with Co(OAc)2
.4H2O to form salcomine (3.34).
57 The 
successfully prepared salcomine was subsequently used to synthesise 2.24.  The reaction 
was performed in CH3CN while exposed to atmospheric oxygen. The use of pure oxygen 
did not institute a significant change on the yield. Scheme 3.25 shows a proposed 
mechanism for the oxidation of 3.2 using salcomine in the presence of O2.
65 
 




































Scheme 3.25: Mechanism for the oxidation of 3.2 to afford the 1,4-benzoquinone 2.24. 
 
The target compound 2.24 was obtained in a yield of 65%. The 1H NMR spectrum of 2.24 
was characterised by the presence of two downfield singlets at δH 6.50 and 6.42 due to H-3 
and H-5 (Fig. 3.4). The presence of a signal due C-1 and C-4 at δC 188.0 in the 
13C NMR 
spectrum confirmed the presence of the benzoquinone moi ty (Fig. 3.5). This was further 
confirmed by the IR absorption band at 1615 cm-1. The  1H and 13C NMR data for synthetic 
2.24 are identical with those reported for the natural product isolated from Gunnera 
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2.02.53.03.54.04.55.05.56.06.57.0 ppm  
 
Figure 3.4: 1H NMR spectrum (CDCl3, 400 MHz) of 2.24. 
 
 
200 180 160 140 120 100 80 60 40 20 0 ppm  
 
Figure 3.5: 13C NMR spectrum (CDCl3, 100 MHz) of 2.24. 
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3.6 Synthesis of 2-isopentyl-6-methylbenzo-1,4-quino e (2.25) 
 
The synthesis of 2-isopentyl-6-methylbenzo-1,4-quinone (2.25) was achieved in a two-step 
process (Scheme 3.23) . The first was the Pd/C catalysed hydrogenation of 3.2 to obtain 2-
isopentyl-6-methylphenol (3.35). The product 3.35 was obtained in a quantitative yield. 1H
NMR was used to confirm successful reduction, an upfield shift of signals due to H-1’ and 
H-2’ was observed with the expected splitting pattern. The signals for H-1’ and H-2’ were 
observed at δH 2.61 (2H, br t, J = 8.0 Hz) and 1.52 (2H, m) in the 
1H NMR spectrum of 
3.35 confirming successful reduction of the double bond. The molecular formula of 3.35 
was confirmed by HRMS (ESI-) ([M-H] - obsd. m/z 177.1275, calc. for C12H17O  177.1279). 
The final product was synthesised by oxidising 3.35 with salcomine to obtain a 1,4-
benzoquinone 2.25 in a yield of 79%. The 1H NMR spectrum (Fig. 3.6) of 2.25 was 
characterised by the presence of two downfield singlets at δH 6.56 (1H, s) and  6.51 (1H, s) 
due to H-3 and H-5. The IR absorption band at 1648 cm-1 confirms the presence of the 
benzoquinone moiety. This was further confirmed by the presence of the signal due to C-1 
and C-4 at δC 188.1 in the 
13C NMR spectrum (Fig. 3.7).  
 


















99% 79%  
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1.52.02.53.03.54.04.55.05.56.06.57.0 ppm  
 
Figure 3.6: 1H NMR spectrum (CDCl3, 400 MHz) of 2.25. 
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Figure 3.7: 13C NMR spectrum (CDCl3, 100 MHz) of 2.25. 
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3.7 Synthesis of 2-(3,7-dimethylocta-2,6-dienyl)-6-methyl-1,4-benzoquinone  
      (2.26). 
 
The synthetic route towards the synthesis of 2-(3,7dimethyl-octa-2,6-dienyl)-6-methyl-
1,4-benzoquinone (2.26), was similar to the one followed during the synthesis of 2-methyl-
6-(3-methyl-2-butenyl)benzo-1,4-quinone. The only difference was the use of geranyl 
bromide instead of prenyl bromide for the regioselectiv  o-alkylation step. Therefore, the 
previously synthesised 3.23 was reacted with Mg to form a Grignard type reagent 3.31. 
The Grignard reagent was subsequently transmetallated with Li2CuCl4 and finally coupled 















































Scheme 3.27: Synthesis of 2-(3,7-dimethylocta-2,6-dienyl)-6-methyl-1,4- 
                       benzoquinone (2.26).     
 
1H NMR analysis confirmed successful coupling by the pr sence of the signal at δH 3.39 
(2H, d, J = 7.1 Hz), due to the methylene protons (2H-1’). The signal demonstrated the 
expected upfield shift since the signal was observed at δH 4.00 in the starting material 
(geranyl bromide) 1H NMR spectrum. The successful synthesis of 3.36 was subsequently 
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followed by demethylation using Shindo et al.’s approach.53  The product 3.37 was 
obtained in a yield of 77%. The 1H NMR spectrum of 3.37 demonstrated the expected 
absence of signal due to the OMe group and the presenc  of a broad singlet at δH 5.18 due 
to the phenolic proton (Fig. 3.8). The presence of the phenolic moiety was also confirmed 
by the IR absorption band observed at 3536.2 cm-1. The molecular formula of 3.37 was 






7.07.27.4 ppm 3.4 ppm
 
 
Figure 3.8: 1H NMR (CDCl3, 400 MHz) spectrum of 3.37. 
 
The synthesis of 3.37 was subsequently followed by an oxidation reaction with salcomine 
in the presence of oxygen. The product 2.26 was obtained in a yield of 63%. The 1H NMR 
spectrum of 2.26 was characterised by the two downfield singlets at δH 6.56 and 6.48 due 
to H-3 and H-5 (Fig. 3.9). The acquired 13C NMR spectrum of 2.26 demonstrated two 
signals at δC 188.0 and 187.9 due to C-4 and C-1, which confirmed the presence of the 
benzoquinone moiety. The observed IR absorption bands t 1651, 1614 cm-1 also confirm 
the presence of a benzoquinone moiety. The 1H and 13C NMR data for synthetic 2.26 
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correlated with those reported for the natural product isolated from brown alga, 
Cystophora harveyi.66  
 
 
2.02.53.03.54.04.55.05.56.06.5 ppm  
 
Figure 3.9: 1H NMR (CDCl3, 400 MHz) spectrum of 2.26. 
 
3.8 Synthesis of 2-(3,7-dimethyloctyl)-6-methyl-1,4-benzoquinone (2.27). 
 
The successful synthesis of 2.26 provided the relevant foundation for the synthesis of 2.27. 
Like the synthesis of 2.25, the synthesis of 2.27 involved two steps. The first step was the 
reductive hydrogenation, while the second step was the oxidation using salcomine (Scheme 
3.28). The synthesised 3.37 was reduced using H2 in the presence of 10% Pd/C. The 
product was obtained in a quantitative yield. The structure of 2.27 was confirmed using 
NMR. The characteristic triplet signals at δH 5.34 (H-2’)  and 5.09 (H-6’) in the 
1H NMR 
spectrum of 3.37 had disappeared which was an indication that the double bonds had been 
reduced (Fig. 3.10). The 13C NMR spectrum of 3.38 demonstrated an upfield shift of C-2’ 
and C-6’, the signals were observed at δC 120.3 and 123.8 respectively (Fig. 3.11). The 
molecular formula of 3.38 was confirmed by HRMS (ESI-) ([M-H] - obsd. m/z 247.2217, 
calc. for C17H27O 247.2215). The synthesis of 3.38 was subsequently followed by an 
oxidation step. The product 2.27 was obtained in a yield of 75%. The structure of 2.27 was 
confirmed using NMR spectroscopy. The resonances at δC 187.9 and 187.8 in the 
13C NMR 
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spectrum were diagnostic of a benzoquinone moiety. The IR spectrum of 2.27 showed 
absorption band at 1651 cm-1 that also confirmed the presence of a benzoquinone moi ty. 
The molecular formula of 2.27 was confirmed by HRMS (ESI+) ([M+H] + obsd. m/z 




























Scheme 3.28: Synthetic route towards 2-(3,7-dimethyloctyl)-6-methyl-1,4-  
                       benzoquinone (2.27). 
 
 
3.9 Approaches Towards the Synthesis of Analogue 2.28. 
 
Since the synthesis of 2.28 also involved regioselective alkyl coupling, demethylation, 
regioselective bromination and methylation and oxidation, the formulated synthetic 
strategy was based on the synthetic strategies that were used in the synthesis of2.24-
2.27.22,37,41,53 In addition the synthesis of 2.28 was also used as a yardstick to test the 
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1.52.02.53.03.54.04.55.05.56.06.57.0 ppm  
 
Figure 3.10: 1H NMR spectrum (CDCl3, 400 MHz) of 2.27. 
 
 
30405060708090100110120130140150160170180190 ppm  
 
Figure 3.11: 13C NMR spectrum (CDCl3, 100 MHz) of 2.27. 
 



































Scheme 3.29: Proposed synthetic route towards 2.28. 
 
The synthesis of 2.28 started with the synthesis of 3.39 from 1.4-dibromobutane (1 eq) and 
o-bromoanisole (2 eq) (3.27) using Burns’s approach.41 Unfortunately the product was 
obtained along with side products 3.41 and 3.42, consequently a low yield of 43% was 
obtained. The upfield shift of H-1’ in the 1H NMR spectrum was the first indication of 
successful coupling. The successful coupling was indicated by the presence of a triplet 
resonance at δC 2.65 due to H-1’, which integrated for four protons in the 
1H NMR 
spectrum of 3.39. The presence of only two resonances at δC 2.65 (4H, t, J = 7.5 Hz) and 














Since an unsatisfactory yield was obtained in the synthesis of 3.39, another synthetic route 
was formulated. Instead of reacting o-bromoanisole (2 eq) (3.27) and 1,4-dibromobutane (1 
eq), equimolar amounts were used in order to form 3.41as the major product. The product 
3.41 was obtained in a yield of 69%. It was subsequently reacted with 3.28 to obtain 3.39 
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with an improved yield of 68%. Therefore, the subsequent step was the demethylation of 
3.39 employing the approach described by Shindo et al.53 The product 3.40 was 
successfully obtained in a yield of 65%. The absence of the characteristic resonance at δC 
3.83 (6H, s) due to OCH3 in the 
1H NMR spectrum was the first indication of successful 
demethylation. The IR absorption band at 3487 cm-1 onfirms the presence of the phenolic 
moiety.  
 
The synthesis of 2.28 could not be completed. Progress in this synthesis wa  retarded by 
the challenges that were experience during the attemp ed bromination of 3.40. Therefore, 





































Scheme 3.30: Approaches towards the total synthesis of 2.28.    
 
In conclusion, the naturally occurring, 2-methyl-6-(3-methyl-2-butenyl)-benzo-1,4-quinone 
(2.24) was synthesised in five steps. The synthetic protocol employed in the synthesis of 2-
methyl-6-(3-methyl-2-butenyl)-benzo-1,4-quinone (2.24) was subsequently employed in 
the synthesis of the analogues 2.25-2.27. The three analogues were distinguishable from 
2.24 only by the nature of the side chain. The analogue 2-(3,7-dimethylocta-2,6-dienyl)-6-
methyl-1,4-benzoquinone (2.26) with a longer side was synthesised with the same 
synthetic strategy.  The applicability of the formulated synthetic strategy in the synthesis of 
2.26-26.8, suggest that a reliable synthetic approach characterised by consistency, wide 
applicability and mild conditions has been developed. The results obtained also signify that 
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copper-mediated transformation is a potent synthetic strategy for regioselective ortho-
prenylation of a phenol.  
 
The synthesis of 2-methyl-6-(3-methyl-2-butenyl)-benzo-1,4-quinone (2.24) has been 
reported by other groups. Khanna and Singh prepared the compound by direct prenylation 
of 2-methyl-1,4-benzoquinone.67 However this method leads to the formation of 1:1 
mixtures of the 2-methyl-5-(3-methyl-2-butenyl)-benzo-1,4-quinone and 2-methyl-6-(3-
methyl-2-butenyl)-benzo-1,4-quinone (2.24) isomer and is not suitable for large scale 
preparation or the synthesis of analogues. 
 
During the cause of our investigation, we also became aware of a paper by Shaojun.68 
However this paper was not accessible to us and the abstract did not give a clear indication 
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4.1 Conclusion and Future Work 
 
The research presented in this dissertation demonstrated the pivotal role that organic synthesis 
plays in natural product chemistry. The naturally occurring biologically active, 2-methyl-6-(3-
methyl-2-butenyl)-benzo-1,4-quinone (2.24) was synthesised in five steps. The synthesis of 
2.24 has been reported previously by Shaojun and also by Khanna and Singh.1,2 They 
employed different strategies and both of these methods are different to the method we 
employed. This further demonstrates that there is no general route towards the synthesis of 
naturally occurring benzoquinones. Our synthetic route also represents the first regioselective 
synthesis of 2.24. Therefore, the synthetic strategy we have developed is a significant addition 
to the arsenal of simple, versatile and regioselectiv  routes towards benzoquinones, which 
have been dominated by synthetic strategies based on the Claisen rearrangement.3,4  
 
Versatility was demonstrated by our synthetic approach during the synthesis of analogues 
2.25-2.28. The critical o-prenylation step was achieved in reproducible good yields. Therefore, 
the same transformation can be employed in the synthesis of bioactive prenylated aromatic 
compounds. Prenylated aromatic natural products have been reported to exhibit antimicrobial 
and antifungal properties.5-7 Consequently, chemists have demonstrated an interest in the 
synthesis of prenylated aromatic compounds. 
 
Although the synthesis of analogues 2.25-2.27 was successfully achieved, the synthesis of 
analogue 2.28 was not completed. Therefore future work would include the completion of the 
synthesis of 2.28.  
 
One of our aims was to test the compounds for antimicrobial and anticancer activity. This was 
to be done in collaboration with biologists from another Department. However, due to time 
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constraints, the results of the assays could not be included in this dissertation. Future work will 
include evaluating of the activity of synthesised compounds in order to ascertain the structure-
activity relationship of the various groups present in compounds 2.24-2.28, and hence to 
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The NMR spectra were obtained in deuterated solvents using a Bruker Avance 400 MHz 
spectrometer. 1H spectra were obtained at 400 MHz and referenced against the residual 
CHCl3 singlet at 7.24 ppm. 
13C spectra were obtained at 100 MHz and were referenc d 
against the central line of the CDCl3 triplet at 77.0 ppm. Abbreviation used: s - singlet, d - 
doublet, t - triplet, q - quartet, m - multiplet. Mass spectra were obtained on a Waters-LCT 
Premier mass spectrometer. Infrared spectra were obtained as thin films (neat) / thin films 
(chloroform) or as nujol mixes using a Perkin-Elmer Spectrum One Spectrometer with a 
scan window of 4000 - 400 cm-1. The spectrum resolution was 1.0 cm-1 and the average 
from 3 scans was taken.  
 
Column chromatography was performed using Merck silica gel 60 PF254 and thin-layer 
chromatography (TLC) was performed using Merck silica gel 60 PF254  supported on 
aluminum backing. Visualisation of compounds on TLC was achieved under UV light 
(254/365 nm) and/or by exposure to iodine vapour or staining with an anisaldehyde 
staining solution. All moisture and air-sensitive ractions were performed under dry 
conditions under nitrogen pressure.  
 
All microwave reactions were conducted on a CEM Focused MicrowaveTM Synthesis 
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5.2 Phenoxide Carbon Alkylation  
 


















Method  A 
 
To a solution of dry diethyl ether (50 ml) and o-cresol (3.1) (0.279 g, 2.58 mmol) was 
slowly added small pieces of metallic sodium (0.237 g, 10.3 mmol).  The mixture was 
stirred for 2 h. Allylic bromide (0.384 g, 2.58 mmol) was added dropwise, after which the 
mixture was refluxed for 10 h. The unreacted metallic sodium metal was quenched using 
methanol. The reaction mixture was acidified with 0.1 M aq HCl. The residue was 
extracted with diethyl ether (3 x 50 ml). The combined extracts were dried with anhydrous 
MgSO4, filtered and concentrated in vacuo. The reaction products were purified using 
silica column chromatography (9:1 hexane-ethyl acetate) to yield compound 3.2 (0.182 g, 
1.03 mmol, 40%) as a yellowish oil and compound 3.3 (0.146 g, 0.825 mmol, 32%) as a 
colourless oil.  
 
Method B 
Procedure A was repeated with all the parameters the same except temperature and 
reaction time. The diethyl ether and o-cresol solution was prepared and kept at 0 oC, 
subsequently allylic bromide was added slowly at this emperature. The temperature of the 
resulting mixture was allowed to rise to room temperature. The reaction mixture was 
stirred overnight. The reaction yielded compound 3.2 (0.259 g, 1.47 mmol, 57%) as a 
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Compound 3.2  
 
1H NMR (400 MHz, CDCl3) δH 6.97 (1H, d, J = 7.4 Hz, H-3), 6.93 (1H, d, J = 7.2 Hz, H-
5), 6.74 (1H, t, J = 7.4 Hz, H-4), 5.30 (1H, t, J = 7.2 Hz, H-2’), 5.11 (1H, br s, OH), 3.33 
(2H, d, J = 7.0 Hz, H-1’), 2.21 (3H, s, CH3), 1.78 (3H, s, H-4’), 1.76 (3H, s, H-5’).  
 
13C NMR (100 MHz, CDCl3) δC 152.9 (C-1), 135.0 (C-3’), 129.0 (C-5), 127.6 (C-3), 126.1 
(C-6), 124.2 (C-2), 122.0 (C-4), 120.2 (C-2’), 30.3 (C-5’), 25.7 (C-1’), 17.9 (C-4’), 15.8 
(6-CH3).  
 
HRMS (ESI-) [M-H] - obsd. m/z 175.1118 (calc. for C12H15O 175.1123).  
 
IR vmax: 3564, 2919, 1594, 1467, 1377, 1257, 1190, 765 cm





1H NMR (400 MHz, CDCl3) δH 7.12 (2H, m, H-3, 5), 6.83 (2H, m, H-4, 6), 5.49 (1H, t, J = 
6.52 Hz, H-2’), 4.51 (2H, d, J = 6.5 Hz, H-1’), 2.22 (3H, s, H-7), 1.78 (3H, s, H-4’), 1.72 
(3H, s, H-5’).  
 
13C NMR (100 MHz, CDCl3) δC 157.1 (C-1), 137.1 (C-3’). 130.6 (C-3), 127.1 (C-5), 126.6 
(C-2), 120.4 (C-2’), 120.2 (C-4), 111.5 (C-6), 65.1 (C-1’), 25.8 (C-5’), 18.2 (C-4’), 16.3 
(2-CH3).  
 
HRMS (ESI+) [M+H] +obsd. m/z 177.1283 (calc. for C12H17O 177.1284).  
 
IR vmax: 2917, 1603, 1493, 1237, 1119, 1006, 746, 713 cm
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5.3 Directed ortho-Metalation  
 




     
A solution of Na2CO3 (0.624 g, 5.89 mmol) and o-cresol (3.1) (1.00 g, 5.43 mmol) in dry 
acetone (20 ml) was refluxed under nitrogen for 1 h. To the mixture Me2SO4  (0.685 g, 5.43 
mmol) was added and the mixture was refluxed for a further 3 h. The reaction mixture was 
quenched in water and extracted with ether (3 x 20 ml). The combined extracts were dried 
over anhydrous MgSO4, filtered and concentrated in vacuo. The reaction products were 
purified using silica column chromatography (hexane) to yield compound 3.13 (0.636 g, 
5.12 mmol, 96%) as a colourless oil. 
 
1H NMR (400 MHz, CDCl3) δH 7.12 (2H, m, H-3,5), 6.82 (2H, m, H-4,6), 3.81 (3H, s, 
OCH3), 2.20 (3H, s, CH3),
  
 
13C NMR (100 MHz, CDCl3) δC 157.3 (C-1), 130.6 (C-3), 128.1 (C-5), 120.3 (C-2), 119.3 
(C-4), 110.7 (C-6), 63.9 (OCH3), 14.1 (CH3).  
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To a solution 2-methylanisole (3.13) (0.500 g, 4.09 mmol) in dry THF, n-BuLi (6.5 ml, 
4.09 mmol) was added at -78 oC. The resulting solution was stirred for 1.5 h after which 
prenyl bromide (0.609 g, 4.09 mmol) was added.  Thesolution was allowed to warm to 
room temperature. The reaction was quenched with saturated aqueuous NH4Cl, dried with 
anhydrous MgSO4, filtered and concentrated in vacuo. The material obtained subjected to 
silica column chromatography (1:4, diethyl ether-hexane). Unfortunately the product 3.15 
was not obtained.  
 
The same procedure was repeated several times manipulating the different variables. This 
included changing the solvent from diethyl ether to THF, addition of TMEDA and CuI and 
varying of the temperature. Each experiment was repeated several times but there was no 
product obtained.  
 











To a solution of o-cresol (3.1) (2.50 g, 23.1 mmol) in 20 mL THF, 3,4-dihydro-2H-pyran 
(4.86 g, 57.8 mmol) and anhydrous p-toluenesulfonic acid was added at 0 oC. The resulting 
mixture was stirred for 12 h at 5 oC. The reaction was quenched by basifying with 10% 
NaOH. The residue was extracted with dichloromethane (3 x 50 ml). The combined 
extracts were dried with anhydrous MgSO4, filtered and concentrated in vacuo. The 
  CHAPTER FIVE 
 65
reaction product was purified using silica column chromatography (1:4, diethyl ether-
hexane) to yield compound 3.20 (3.20 g, 16.6 mmol, 72%) as a colourless oil. 
 
1H NMR (400 MHz, CDCl3) δH 7.16 (2H, t, J = 6.5 Hz, H-3,5), 7.09 (1H, d, J = 7.71 Hz, 
H-6), 6.91 (1H, t, J = 7.7 Hz, H-4), 5.45 (1H, t, J = 3.1 Hz, H-1’), 3.93 (1H, td, J = 10.1, 
2.8 Hz, Hax-5’) 3.63 (1H, m, Heq-5’), 2.30 (3H, s, CH3), 1.71-2.06 (6H, m, H-2’,3’,4’) 
 
13C NMR (100 MHz, CDCl3) δC 155.1 (C-1), 130.6 (C-3), 127.3 (C-5), 126.7 (C-2), 121.2 
(C-4), 114.2 (C-6), 96.1 (C-1’), 62.0 (C-5’), 30.6 (C-2’), 25.3 (C-4’), 19.0 (C-3’), 16.2 (2-
CH3).  
 
HRMS (ESI+) [M+Na]+ obsd. m/z 215.1048 (calc. for C12H16O2Na  215.1047).  
 
IR vmax: 2940, 1492, 1235, 1035, 966, 746 cm
-1. 
 






To a solution of compound 3.20 (0.500 g, 2.60 mmol) in dry THF, n-BuLi (4.16 ml, 2.60 
mmol) was added at -100 oC. The resulting solution was stirred for 1.5 h; prenyl bromide 
(0.387 g, 2.60 mmol) was added.  The solution was allowed to warm up to room 
temperature. The reaction was quenched by the addition of water and the products 
extracted with diethyl ether (3 x 20 ml). The combined extracts were washed with 10% 
NaOH, water, dried with anhydrous MgSO4, filtered and concentrated in vacuo. The 
reaction product was subjected to silica column chromatography (1:4, diethyl ether-
hexane). Unfortunately the product 3.21 was not obtained. 
 
The same procedure was repeated several times manipulating the different variables. This 
included changing the solvent from diethyl ether to THF, addition of TMEDA and CuI and 
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5.4 Metal-Halogen Exchange   
 












             
Method A              
 
To a solution of o-cresol (3.1) (1.00 g, 9.26 mmol) in CH2Cl2 (30 ml), was added NBS 
(1.61 g, 9.26 mmol) in CH2Cl2 (30 ml). The mixture was stirred at room temperature for 2 
h. The reaction mixture was acidified with HCl and the aqueous solution was extracted 
with CH2Cl2 (3 x 20 ml). The combined extracts were dried over anhydrous MgSO4, 
filtered and concentrated in vacuo. The reaction products were purified using silica column 
chromatography (1:9; diethyl ether: hexane) to yield compound 3.22 (0.811 g, 4.33 mmol, 




A solution of diisopropylamine (0.0919 g, 0.926 mmol) in CH2Cl2 (2 ml) was added to a 
solution of o-cresol (1.00 g, 9.26 mmol) in CH2Cl2 (10 ml) at 0 
oC. To the resulting 
mixture, a solution of NBS (1.61 g, 9.26 mmol) in CH2 l2 (30 ml) was added over 1 h. The 
mixture was stirred for 2 h at 0 oC. The reaction mixture was acidified with HCl and the 
aqueous solution was extracted with CH2 l2 (3 x 20 ml). The combined extracts were dried 
over anhydrous MgSO4, filtered and concentrated in vacuo. The reaction products were 
purified using silica column chromatography (1:9, diethyl ether-hexane) to yield 
compound 3.21 (1.26 g, 6.74 mmol, 73%) as a colourless oil. 




1H NMR (400 MHz, CDCl3) δH 7.27 (1H, d, J = 7.9 Hz, H-3), 7.04 (1H, d, J = 7.5 Hz, H-
5), 6.69 (1H, t, J = 7.7 Hz, H-4), 5.54 (1H, br s, OH), 2.28 (3H, s, CH3). 
13C NMR (100 MHz, CDCl3) δC 150.4 (C-1), 130.4 (C-3), 129.4 (C-5), 125.9 (C-6), 121.2 
(C-4), 110.2 (C-2), 16.6 (CH3).  
 
HRMS (ESI-) [M-H] - obsd. m/z 184.9602 (calc. for C7H6O
77Br 184.9602).  
 





1H NMR (400 MHz, CDCl3) δH 7.25 (1H, m, H-3), 7.18 (1H, dd, J = 8.5, 2.5 Hz, H-5), 
6.66 (1H, d, J = 8.5 Hz, H-6), 4.82 (1H, br s, OH), 2.24 (3H, s, CH3).  
 
13C NMR (100 MHz, CDCl3) δC 152.9 (C-1), 133.5 (C-3), 129.7 (C-5), 126.2 (C-2), 116.5 
(C-4), 112.5 (C-6), 15.6 (CH3).  
 







             
A solution of Na2CO3 (0.678 g, 6.40 mmol) and compound 3.22 (1.00 g, 5.35 mmol) in dry 
acetone (20 ml) was refluxed under nitrogen for 1 h. To the mixture Me2SO4  (0.743g, 5.89 
mmol) was added and the mixture was refluxed for a further 3 h. The reaction mixture was 
quenched with water and extracted with ether (3 x 20 ml). The combined extracts were 
dried over anhydrous MgSO4, filtered and concentrated in vacuo. The reaction products 
were purified using silica column chromatography (hexane) to yield compound 3.23 (1.02 
g, 5.08 mmol, 95%) as a yellowish oil.  
 
  CHAPTER FIVE 
 68
1H NMR (400 MHz, CDCl3) δH 7.35 (1H, d, J = 7.9 Hz, H-3), 7.09 (1H, d, J = 7.6 Hz, H-
5), 6.86 (1H, t, J = 7.8 Hz, H-4), 3.85 (3H, s, OCH3), 2.35 (3H, s, CH3).   
 
13C NMR (100 MHz, CDCl3) δC 155.4 (C-1), 131.0 (C-3), 130.3 (C-5), 128.0 (C-6), 125.1 
(C-4),117.3 (C-2), 60.1 (OCH3), 16.5 (CH3).  
 
HRMS (ESI+) [M+H] + obsd. m/z 200.9841 (calc. for C8H10O
77Br 200.9842).  
 
IR vmax: 2930, 1467, 1415, 1228, 1004, 1083, 843, 769 cm
-1. 
 










2-Bromo-6-methylanisole 3.23 (0.500 g, 2.49 mmol) was dissolved in dry diethyl ether (10 
ml), under nitrogen. The resulting solution was cooled to 0 oC before adding TMEDA 
(0.53 ml, 3.55 mmol) subsequently followed by the addition of n-BuLi (2.1 ml, 3.55 
mmol). The mixture was allowed to stir for 20 min before adding prenyl bromide. The 
reaction was allowed to stir overnight and subsequently quenched using saturated aqueous 
NH4Cl (10 ml) and extracted with diethyl ether (3 x 10 ml). The combined extracts were 
dried with anhydrous MgSO4, filtered and concentrated in vacuo. The reaction products 
were purified using silica column chromatography (1:4 diethyl ether-hexane) to yield 
compound 3.15 (0.057 g, 0.299 mmol, 12%) as a yellowish oil,   
 
1H NMR (400 MHz, CDCl3) δH 7.00 (2H, d, J = 7.4 Hz, H-3,5), 6.93 (1H, dd, J = 7.5, 6.4 
Hz, H-4), 5.27 (1H, t, J = 7.2 Hz, H-2’), 3.72 (3H, s, OCH3), 3.35 (2H, d, J = 7.2 Hz, H-
1’), 2.28 (3H, s, CH3), 1.72 (6H, s, H-4’, 5’).
  
 
13C NMR (100 MHz, CDCl3) δC 156.6 (C-1), 134.6 (C-3’), 132.2 (C-3), 130.9 (C-5), 129.0 
(C-6), 127.7 (C-2), 124.0 (C-4), 123.3 (C-2’), 60.2 (OCH3), 29.7 (C-1’), 25.7 (C-5’), 17.8 
(C-4’), 16.1 (CH3).  
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HRMS (ESI+) [M+H] + obsd. m/z 191.1432 (calc. for C13H19O 191.1433). 
 
IR vmax: 2926, 1713, 1511, 1467, 1377, 1254, 1015, 769 cm
-1.         
   
5.5 Copper (II)-Mediated Regioselective Alkylation   
 











Compound 3.27 (1.50 g, 8.02 mmol) was added slowly to a mixture of Mg (0.220 g, 9.05 
mmol) turnings and 20 ml of dry THF under nitrogen. The resulting mixture was allowed 
to reflux for 3 h. The mixture was cannulated into a solution of prenyl bromide (1.19 g, 
8.02 mmol) and 1.5 ml of 0.1 M Li2CuCl4/THF solution, stirring at 0 
oC under nitrogen. 
The reaction mixture was allowed to warm to room tep rature and after 3 h another 1.5 
ml of 0.1 M Li2CuCl4/THF was added. After 6 h, the last portion of 1.5 ml of 0.1 M 
Li2CuCl4/THF was added. After 24 h the reaction was quenched with distilled water (20 
ml) and extracted with ethyl acetate (3 x 20 ml).  The organic layer was washed with dilute 
HCl, water and brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo.  
The reaction products were purified using silica column chromatography (hexane) to yield 
compound 3.30 (1.15 g, 6.50 mmol, 81%) as colourless oil. 
 
 1H NMR (400 MHz, CDCl3) δH 7.17 (2H, m, H-3,5), 6.90 (1H, t, J = 7.4 Hz, H-4), 6.86 
(1H, d, J = 8.1 Hz, H-3), 5.33 (1H, t, J = 7.2 Hz, H-2’), 3.86 (3H, s, OCH3), 3.34 (2H, d,  J 
= 7.7 Hz, H-1’), 1.76 (3H, s, H-4’), 1.73 (3H, s, H-5’).  
 
13C NMR (100 MHz, CDCl3) δC 157.3 (C-1), 132.4 (C-3’), 130.1 (C-3), 129.3 (C-5), 126.8 
(C-2), 122.6 (C-4), 120.4 (C-2’), 110.2 (C-6), 55.3 (OCH3), 28.4 (C-1’), 25.8 (C-5’), 17.7 
(C-4’).  
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HRMS (ESI+) [M+H] + obsd. m/z 177.1276 (calc. for C12H17O 177.1275).  
 
IR vmax: 2968, 1599, 1462, 1240, 1028, 750. cm
-1.           
               










2-Bromo-6-methylanisole(3.23) (0.500 g, 2.49 mmol) was added slowly to a mixture of 
Mg turnings and 15 ml of dry THF under nitrogen. The resulting mixture was allowed to 
reflux for 5 h. The mixture was cannulated into a solution of allylic bromide (0.371 g, 2.49 
mmol) and 1.5 ml of 0.1 M Li2CuCl4/THF solution, stirring at 0 
oC under nitrogen. The 
reaction mixture was allowed to warm to room temperature and after 3 h another 1.5 ml of 
0.1 M Li2CuCl4/THF was added. After 6 h, the last portion of 1.5 ml of 0.1 M 
Li2CuCl4/THF was added. After 24 h the reaction was quenched with distilled water (20 
ml) and extracted with ethyl acetate (3 x 20 ml).  The organic layer was washed with dilute 
HCl, water and brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo.  
The reaction products was purified using silica column chromatography (1:4, diethyl ether-
hexane) to yield compound 3.15 (0.336 g, 1.77 mmol, 71%) as yellowish oil;  
 
1H NMR (400 MHz, CDCl3) δH 7.00 (2H, d, J = 7.4 Hz, H-3,5), 6.93 (1H, dd, J = 7.5, 6.4 
Hz, H-4), 5.27 (1H, t, J = 7.2 Hz, H-2’), 3.72 (3H, s, OCH3), 3.35 (2H, d, J = 7.2 Hz, H-
1’), 2.28 (3H, s, CH3), 1.72 (6H, s, H-4’, 5’).
  
 
13C NMR (100 MHz, CDCl3) δC 156.6 (C-1), 134.6 (C-3’), 132.2 (C-3), 130.9 (C-5), 129.0 
(C-6), 127.7 (C-2), 124.0 (C-4), 123.3 (C-2’), 60.2 (OCH3), 29.7 (C-1’), 25.7 (C-5’), 17.8 
(C-4’), 16.1 (CH3).  
 
HRMS (ESI+) [M+H] + obsd. m/z 191.1432 (calc. for C13H19O 191.1433).  
 
IR vmax: 2926, 1713, 1511, 1467, 1377, 1254, 1015, 769 cm
-1.         
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5.5.3 Demethylation of 2-bromo-6-methylanisole (3.23) 
 
2-Bromo-6-methylanisole (3.23) (0.100 g, 0.500mmol) was dissolved in DMF (5 ml), to 
the resulting solution iodocyclohexane (1.05 g, 5 mmol)  was added. The reaction mixture 
was subsequently refluxed for 8 h under nitrogen. The obtained reaction mixture was 
cooled and mixed with water (25 ml) and extracted with ethyl acetate (3 x 20 ml). The 
organic layer was washed with NaHSO3 and brine, dried over anhydrous MgSO4, filtered 
and concentrated in vacuo. The reaction products were purified using silica column 
chromatography (1:9, diethyl ether-hexane) to yield compound 3.22 (0.0804 g, 0.430 
mmol,  86%) as a colourless oil. 
 
1H NMR (400 MHz, CDCl3) δH 7.27 (1H, d, J = 7.9 Hz, H-3), 7.04 (1H, d, J = 7.5 Hz, H-
5), 6.69 (1H, t, J = 7.7 Hz, H-4), 5.54 (1H, br s, OH), 2.28 (3H, s, CH3). 
 
13C NMR (100 MHz, CDCl3) δC 150.4 (C-1), 130.4 (C-3), 129.4 (C-5), 125.9 (C-6), 121.2 
(C-4), 110.2 (C-2), 16.6 (CH3).  
 
HRMS (ESI-) [M-H] - obsd. m/z 184.9602 (calc. for C7H6O
77Br  184.9602).  
 
IR vmax 3512, 1459, 1433, 1217, 1119, 1075, 758 cm
-1. 
 
5.5.4 Attempted demethylation of 3.15 using Zuo’s approach 
 
2-Methyl-6-(3-methyl-2-butenyl)anisole (3.15) (0.190 g, 1.00 mmol) was dissolved in 
DMF (5 ml), to the resulting solution iodocyclohexane (2.10 g, 10 mmol) was added. The 
reaction mixture was subsequently refluxed for 10 h under nitrogen. The obtained reaction 
mixture was cooled and mixed with water (25 ml) and extracted with ethyl acetate (3 x 20 
ml). The organic layer was washed with NaHSO3 and brine, dried over anhydrous MgSO4, 
filtered and concentrated in vacuo. The material obtained subjected to silica column 
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5.5.5 Attempted demethylation of 3.15 using Fang’s approach 
 
To a solution of 2-methyl-6-(3-methyl-2-butenyl)anisole (3.15) (0.100 g, 0.526 mmol) in 
dry DMF (0.10 ml, 1.58 mmol), was added LiCl (0.0669 g, 1.58 mmol). The mixture was 
irradiated under microwave (300 W, 300 oC) for 5-30 min. The resulting mixture was 
quenched with dilute HCl, and extracted with ethyl acetate (3 x 20 ml). The organic layer 
was dried over anhydrous MgSO4, filtered and concentrated in vacuo. The material 
obtained subjected to silica column chromatography (1:4, diethyl ether-hexane). 
Unfortunately the product 3.2 was not obtained.  
 











                                                       
To a mixture of 10 ml dry THF and metallic lithium (0.039 g, 5.68 mmol), stirring at 0 oC 
under nitrogen, was added ethylenediamine (0.478 g, 7.95 mmol). Compound 3.15 (0.200 
g, 1.05 mmol) was added and the solution was allowed to stir at 0 oC for 2 h. The 
remaining lithium was separated from the resulting deep blue solution and quenched with 
methanol. The pink reaction mixture was quenched with distilled water (10 ml) and 
extracted with diethyl ether (3 x 20 ml). The organic layer was washed with dilute HCl, 
water and brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The 
reaction products were purified using silica column chromatography (1:4; diethyl ether-
hexane) to yield compound 3.2 (0.154 g, 0.874 mmol, 84%) as a yellowish oil.  
 
1H NMR (400 MHz, CDCl3) δH 6.97 (1H, d, J = 7.4 Hz, H-3), 6.93 (1H, d, J = 7.2 Hz, H-
5), 6.74 (1H, t, J = 7.4 Hz, H-4), 5.30 (1H, t, J = 7.2 Hz, H-2’), 5.11 (1H, br s, OH) 3.33 
(2H, d, J = 7.0 Hz, H-1’), 2.21 (3H, s, CH3), 1.78 (3H, s, H-4’), 1.76 (3H, s, H-5’). 
 
13C NMR (100 MHz, CDCl3) δC, 152.9 (C-1), 135.0 (C-3’), 129.0 (C-5), 127.6 (C-3), 
126.1 (C-6), 124.2 (C-2), 122.0 (C-2’), 120.2 (C-4), 30.3 (C-1’), 25.7 (C-5’), 17.9 (C-4’), 
15.8 (CH3).  
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HRMS (ESI-) [M-H] - obsd. m/z 175.1118 (calc. for  C12H15O 175.1123).  
 
IR vmax: 3564, 2919, 1594, 1467, 1377, 1257, 1190, 765 cm
-1.   
 














To a purple solution of (KSO3)2NO (0.060 g, 0.222 mmol) and KH2PO4
.3H2O (0.080 g 
0.420 mmol) in 10 ml water was added a solution of 2-methyl-6-(3-methyl-2-
butenyl)phenol (3.2) (0.020 g, 0.114 mmol) in 10 ml methanol. The resulting mixture was 
vigorously stirred overnight. The reaction mixture was extracted with CH2Cl2 (2 x 20 ml). 
The combined extracts were dried with anhydrous MgSO4, filtered and concentrated in
vacuo. The reaction product was purified using silica column chromatography (1:4, 
diethylether-hexane) to yield compound 2.24 as a yellowish oil (0.021 g, 0.110 mmol, 




2-Methyl-6-(methyl-2-butenyl)phenol (3.2) (0.100 g, 0.569 mmol) was dissolved in dry 
CH3CN (20 ml) and salcomine (0.244 g, 0.750 mmol) was added to the resulting solution 
and the reaction mixture was allowed to stir for 24 h at room temperature. The resulting 
solution was filtered, the solids were discarded, quenched with water and extracted with 
diethyl ether (3 x 20 ml). The combined extracts were dried with anhydrous MgSO4, 
filtered and concentrated in vacuo. The reaction product was purified using silica column 
chromatography (1:4, diethylether-hexane) to yield compound 2.24 as a yellowish oil 
(0.0704 g, 0.370 mmol, 65%).  
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1H NMR (400 MHz, CDCl3) δH 6.50 (1H, s, H-3), 6.42 (1H, s, H-5), 5.01 (1H, bt, J = 7.5 
Hz, H-2’), 3.07 (2H, d, J = 7.6 Hz, H-1’), 2.07 (3H, s, CH3 ), 1.71 (3H, s, H-4’), 1.59 (3H, 
s, H-5’). 
13C NMR (100 MHz, CDCl3) δC 188.0 (C-1, 4), 148.5 (C-6), 145.9 (C-2), 136.2 (C-3’), 
132.3 (C-3, 5), 118.1 (C-2’), 27.7 (C-1’), 25.7 (C-4’), 17.7 (C-5’), 16.0 (CH3).  
 
HRMS (ESI+) [M+Na+MeOH]+ obsd. m/z 245.1153 (calc. for C13H18O3Na 245.1154). 
 
IR vmax: 2919, 1651, 1613, 1437, 1291, 1172, 911 cm
-1. 
 
5.6 Synthesis of [bis-(salicylidene)ethylenediamine]colbalt (Salcomine) (3.34) 
 








To a solution of salicylaldehyde (4.00 g, 32.7 mmol) in boiling ethanol (150 ml), 
athylenediamine (0.982g, 16.4 mmol) was added. The mixture was allowed to stand; 
within 2 min the formation of bright yellow crystals material was observed. The mixture 
was allowed to cool to temperature and subsequently filtered. The crystalline material was 
allowed to dry. The bright yellow crystals were recrystallized from ethanol to yield 
compound 3.33 (3.74g, 13.9 mmol, 82%), the melting point was measured to be 119-121 
oC (literature value 123 oC)  
 
1H NMR (400 MHz, CDCl3) δH 8.37 (2H, s, H-1’), 7.31 (2H, dt, J = 8.8, 1.7 Hz, H-4), 7.24 
(2H, dd, J = 8.5, 1.6 Hz, H-6), 6.96 (2H, d, J = 8.29 Hz, H-3), 6.87 (2H, t, J = 7.45, H-5), 
3.96 (1H, s, H-3),  
 
13C NMR (100 MHz, CDCl3) δC 166.5 (C-1’), 161.0 (C-2), 132.3 (C-4), 131.5 (C-6), 118.8 
(C-1), 118.7 (C-5), 116.7 (C-3), 59.9 (C-3’).  
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IR vmax: 3545, 2967, 2853, 1548, 1653 cm
-1.  
         









To a solution of 3.33 (3.5 g, 13.0 mmol) in 35 ml methanol at 40 oC under nitrogen was 
added NaOH (1 eq) (to dissolved all the crystals). Co(OAc)2
.4H20 (3.24 g, 13.0 mmol) 
dissolved in 5 ml distilled water was subsequently added dropwise. The complexs 
immediately started to precipitate. The mixture was further stirred at 40 oC for 2 h. After 
allowing the solution to cool down to room temperatu e, the precipitate was filtered and 
washed successively with water and absolute ethanol. The precipitate was dried to yield 
cobalt complex 3.34 (2.66g, 8.18 mmol, 62%) as a brownish solid. HRMS (ESI+) [M+H] + 
obsd. m/z 326.0478 (calc. for C16H15O2N2Co  326.0476) 
 
5.7 Synthesis of Analogue 2.25. 
 









      
2-Methyl-6-(3-methyl-2-butenyl)phenol (3.2) (0.200 g, 1.13 mmol) was dissolved in dry 
MeOH (15 ml) and to the resulting solution 10% Pd/C as a catalyst was added. The 
reaction mixture was stirred for 1 h at room temperature under a hydrogen pressure. The 
product, compound 3.35, was obtained (0.199 g, 1.12 mmol, 99%) as a yellowish oil.  
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1H NMR (400 MHz, CDCl3) δH 6.99 (2H, d, J = 7.2 Hz, H-3, 5), 6.79 (1H, t, J = 7.3, H-4), 
4.60 (1H, br s, OH), 2.61 (2H, br t, J = 8.0 Hz, H-1’), 2.27 (3H, s, CH3), 1.65 (1H, m, H-
3’), 1.52 (2H, m, H-2’) 0.97 (6H, d, J = 6.5 Hz, H-4’,5’).  
 
13C NMR (100 MHz, CDCl3) δC 151.9 (C-1), 128.4 (C-5), 128.1 (C-3), 127.6 (C-2) 1 3.0 
(C-6), 120.3 (C-4), 39.3 (C-2’), 28.0 (C-3’), 27.9 (C-1’), 22,5 (C-4’, 5’), 15.8 (CH3).  
 
HRMS (ESI-) [M-H] - obsd. m/z 177.1275 (calc. for C12H17O  177.1279)  
 
IR vmax: 3585, 2954, 1594, 1467, 1187, 827, 741 cm
-1.   
 










   
Compound 3.35 (0.100 g, 0.560 mmol) was dissolved in dry CH3 N (20 ml) and to the 
resulting solution salcomine (0.243 g, 0.747 mmol) was added. The reaction mixture was 
allowed to stir for 24 h at room temperature. The resulting solution was filtered, the solids 
were discarded, quenched with water and extracted with diethyl ether (3 x 20 ml). The 
combined extracts were dried over anhydrous MgSO4, filtered and concentrated in vacuo. 
The reaction product was purified using silica column chromatography (1:4, ethyl acetate-
hexane) to yield compound 2.25 (0.085 g, 0.442 mmol, 79%) as a yellowish oil.
 
1H NMR (400 MHz, CDCl3) δH 6.56 (1H, s, H-3), 6.51 (1H, s, H-5), 2.43 (2H, t, J = 7.8 
Hz, H-1’) 2.07 (3H, s, CH3 ), 1.63 (1H, m, H-3’), 1,39 (2H, q, J = 6.8 Hz, H-2’), 0.95 (6H, 
d, J = 6.5 Hz, H-4’,5’).  
 
13C NMR (100 MHz, CDCl3) δC 188.1 (C-1, 4), 150.1 (C-2), 146.1 (C-6), 133.2 (C-5), 
132.4 (C-3) 37.2 (C-2’), 28.0 (C-3’), 27.2 (C-1’), 22.5 (C-4’, 5’), 16.2 (CH3).  
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HRMS (ESI+) [M+Na]+ obsd. m/z 215.1048 (calc. for C12H16O2Na  215.1047).  
 
IR vmax: 2954, 1648, 1467, 1366, 1291, 1034, 1190, 910 cm
-1. 
 
5.8 Preparation of Analogue 2.26 
 













2-Bromo-6-methylanisole (3.23) (0.800 g, 3.98 mmol) was added slowly to a mixture of 
Mg (0.109 g, 4.50 mmol)  turnings and 20 ml of dry THF under nitrogen. The resulting 
mixture was allowed to reflux for 5 h. The mixture was cannulated into a solution of 
geranyl bromide (0.864 g, 3.98 mmol) and 1.5 ml of 0.1 M Li2CuCl4/THF solution, stirring 
at 0 oC under nitrogen. The mixture was allowed to warm to room temperature and after 3 
h another 1.5 ml of 0.1 M Li2CuCl4/THF was added. After 6 h, the last portion of 1.5 ml of 
0.1 M Li2CuCl4/THF was added. After 24 h the reaction was quenched with distilled water 
(20 ml) and extracted with ethyl acetate (3 x 20 ml).  The organic layer was washed with 
dilute HCl, water and brine, dried over anhydrous MgSO4, filtered, and concentrated in
vacuo.  The reaction product was purified using silica column chromatography (1:4 diethyl 
ether: hexane) to yield compound 3.36 (0.669 g, 2.59 mmol, 65%) as a colourless oil.  
 
1H NMR (400 MHz, CDCl3) δH 
1H NMR (400 MHz, CDCl3) δH 7.05 (2H, d, J = 7.5 Hz, H-
3, 5), 6.99 (1H, t, J = 7.4 Hz, H-4), 5.28 (1H, t, J = 7.0 Hz, H-2’), 5.08 (1H, t, J = 6.8 Hz, 
H-6’), 3.71 (3H, s, OCH3), 3.36 (2H, d, 7.2 Hz, H-1’) 2.27 (3H, s, CH3), 2.06 (2 x 2H, m, 
H-4’, 5’), 1.74 (3H, s, H-10’), 1.69 (3H, s, H-8’), 1.61 (3H, s, H-9’).  
 
13C NMR (100 MHz, CDCl3) δC  156.7 (C-1), 135.9 (C-3’), 131.3 (C-7’), 128.9 (C-5), 
128.2 (C-3), 127.6 (C-2), 124.3 (C-6), 123.9 (C-6’), 123.0 (C-2’), 120.3 (C-4), 61.1 
(OCH3), 39.7 (C-4’), 30.6 (C-1’), 26.6 (C-5’), 25.6 (C-8’), 17.6 (C-9’), 16.2 (C-10), 16.0 
(CH3). 
  CHAPTER FIVE 
 78
IR vmax: 2932, 1715, 1518, 1452, 1372, 1257, 1153, 913 cm
-1.         
 












To a mixture of 10 ml dry THF and metallic lithium (0.0729 g, 10.5 mmol), stirring at 0 oC 
under nitrogen, was added ethylenediamine (0.883 g, 14.7 mmol). Compound 3.36 (0.500 
g, 1.94 mmol) was added and the solution was allowed to stir at 0 oC for 3 h. The 
remaining lithium was separated from the resulting deep blue solution and quenched with 
methanol. The pink reaction mixture was quenched with distilled water (10 ml) and 
extracted with diethyl ether (3 x 20 ml). The organic layer was washed with dilute HCl, 
water and brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo.  The 
reaction product was purified using silica column chromatography (1:4, diethyl ether-
hexane) to yield compound 3.37 (0.364 g, 1.49 mmol, 77%) as a yellowish oil.  
 
1H NMR (400 MHz, CDCl3) δH 7.02 (1H, d, J = 7.4 Hz, H-3), 6.97 (1H, d, J = 7.4 Hz, H-
5), 6.78 (1H, t, J = 7.4 Hz, H-4), 5.34 (1H, t, J = 7.2 Hz, H-2’), 5.17 (1H, br s, OH), 5.09 
(1H, t, J = 7.6 Hz, H-6’), 3.38 (2H, d, J = 7.4 Hz, H-1’), 2.25 (3H, s, CH3), 2.12 (2 x 2H, 
m, H-4’, 5’), 1.80 (3H, s, H-10’), 1.71 (3H, s, H-8’), 1.62 (3H, s, H-9’).  
 
13C NMR (100 MHz, CDCl3) δC  152.9 (C-1), 138.7 (C-3’), 132.0 (C-7’), 129.0 (C-5), 
127.5 (C-3), 126.1 (C-2), 124.4 (C-6), 123.8 (C-6’), 121.9 (C-2’), 120.3 (C-4), 39.7 (C-4’), 
30.3 (C-1’), 26.3 (C-5’), 25.7 (C-8’), 17.7 (C-9’), 16.1 (C-10), 15.8 (CH3)  
 
HRMS (ESI+) [M+Na]+ obsd. m/z 267.1726 (calc. for C17H24ONa 267.1725).  
 
IR vmax: 3536, 2918, 1651, 1614, 1438, 1375, 1291, 912 cm
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5.8.3 Preparation of 2-(3,7-dimethylocta-2,6-dienyl)-6-methyl-1,4-benzoquinone  
         (2.26) 
 











Compound 3.37 (0.150 g, 0.614 mmol) was dissolved in dry CH3 N (20 ml) and 
salcomine (0.262 g, 0.805 mmol) was added to the resulting solution and the reaction 
mixture was allowed to stir for 24 h at room temperatu e. The resulting solution was 
filtered, the solids discarded, and the filtratequenched with water and extracted with diethyl 
ether (3 x 20 ml). The combined extracts were dried with anhydrous MgSO4, filtered and 
concentrated in vacuo. The reaction product was purified using silica column 
chromatography (1:9, ethyl acetate-hexane) to yield compound 2.26 (0.100 g, 0.387 mmol, 
63%) as a yellowish oil. 
 
1H NMR (400 MHz, CDCl3) δH 6.56 (1H, s, H-3), 6.48 (1H, s, H-5), 5.16 (1H, bt, J = 7.5 
Hz, H-2’), 5.09 (1H, t, J = 6.9 Hz, H-6’), 3.14 (2H, d, J = 7.6 Hz, H-1’), 2.10 (1H, m, H-4’, 
5’), 2.07 (3H, d, J = 1.72, CH3), 1.70 (3H, s, H-10’), 1.63 (3H, s, H-8’), 1.61 (3H, s, H-9).  
 
13C NMR (100 MHz, CDCl3) δC  188.0 (C-4), 187.9 (C-1), 148.5 (C-2), 145.8 (C-6), 139.8 
(C-3’), 133.2 (C-5), 132.2 (C-3), 131.8 (C-7’), 123.9 (C-6’), 118.0 (C-2’), 39.6 (C-4’), 27.5 
(C-1’), 26.4 (C-5’), 25.6 (C-8’), 17.6 (C-9’), 16.1 (C-10’), 15.9 (CH3).  
 
HRMS (ESI+) [M+H] + obsd. m/z 259.1696 (calc. for C17H23O2 259.1695). 
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5.9 Syntheis of Analogue 2.27 
 










Compound 3.37 (0.200 g, 0.818 mmol was dissolved in dry MeOH (15ml) and to the 
resulting solution 10% Pd/C as a catalyst was added. The reaction mixture was stirred for 1 
h at room temperature under a hydrogen atmosphere. Th  product 3.38 was obtained 
(0.199 g, 0.801 mmol, 99%) as a yellowish oil. 
 
1H NMR (400 MHz, CDCl3) δH 6.99 (2H, d, J = 7.5 Hz, H-3, 5), 6.79 (1H, t, J = 7.5 Hz, H-
4), 4.60 (1H, br s, OH), 2.61 (2H, m, H-1’), 2.77 (3H, s, CH3), 1.69-1.11 (10H, m, H-2’, 3’, 
4’, 5’, 6’, 7’), 0.97 (3H, d, J = 6.4 Hz, H-10’), 0.89 (6H, d, J = 6.6 Hz, H-8’, 9’). 
 
13C NMR (100 MHz, CDCl3) δC  151.7 (C-1), 128.4 (C-3), 128.2 (C-5), 127.6 (C-2), 123.0 
(C-6), 120.2 (C-4), 39.3 (C-6’), 37.1 (C-2’, 4’), 32.8 (C-3’), 27.9 (C-7’), 27.6 (C-5’), 24.6 
(C-1’), 22.6(C-8’, 9), 19.6 (C-10’), 15.8 (CH3).  
 
HRMS (ESI-) [M-H] - obsd. m/z 247.2217 (calc. for C17H27O 247.2215).  
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Compound 3.38 (0.100 g, 0.402 mmol) was dissolved in dry CH3 N (20 ml) and 
salcomine (0.196 g, 0.604 mmol) was added to the resulting solution and the reaction 
mixture was allowed to stir for 24 h at room temperatu e. The resulting solution was 
filtered, the solids were discarded, quenched with ater and extracted with diethyl ether (3 
x 20 ml). The combined extracts were dried with anhydrous MgSO4, filtered and 
concentrated in vacuo. The reaction product was purified using silica column 
chromatography (1:4-diethylether: hexane) to yield compound 2.27 (0.0792 g, 0.301 
mmol, 75%) as a yellowish oil. 
 
1H NMR (400 MHz, CDCl3) δH 6.56 (1H, s, H-3), 6.51 (1H, s, H-5), 2.43 (2H, m, H-1’), 
2.07 (3H, s, CH3), 1.56-1.12 (10H, m, H-2’, 3’, 4’, 5’, 6’, 7’), 0.93 (3H, d, J= 6.5, H-10’), 
0.88 (6H, d, 6.5 Hz, H-8’, 9’). 
 
13C NMR (100 MHz, CDCl3) δC 187.9 (C-4), 187.8 (C-1), 150.1 (C-2), 145.9 (C-6), 133.0 
(C-5), 132.2 (C-3), 39.2 (C-6’), 36.9 (C-2’), 35.1 (C-4’), 32.6 (C-3’), 27.9 (C-7’), 26.8 (C-
5’), 24.6 (C-1’), 22.6 (C-8’), 22.5 (C-9’), 19.4 (C-10’), 16.0 (CH3).  
 
HRMS (ESI+) [M+H] + obsd. m/z 263.2012 (calc. for C17H27O2 263.2013).   
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5.10 Approach towards synthesis of bis-benzoquinone (2.28)  
 


















3.39 3.41 3.423.27  
                                   
 
Compound 3.27 (1.50 g, 8.02 mmol) was added slowly to a mixture of Mg (0.220 g, 9.05 
mmol) turnings and 20 ml of dry THF under nitrogen. The resulting mixture was allowed 
to reflux for 3h. The mixture was cannulated into a solution of 1,4-dibromobutane (0.866 
g, 4.01 mmol) and 1.5 ml of 0.1 M Li2CuCl4/THF solution, stirring at 0 
oC under nitrogen. 
The reaction mixture was allowed to warm to room tep rature and after 3 h another 1.5 
ml of 0.1 M Li2CuCl4/THF was added. After 6 h, the last portion of 1.5 ml of 0.1 M 
Li2CuCl4/THF was added. After 24 h the reaction was quenched with distilled water (20 
ml) and extracted with ethyl acetate (3 x 20 ml).  The organic layer was washed with dilute 
HCl, water and brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo.  
The solid residure was purified using silica column chromatography (hexane) to yield three 
compounds. 
 
Compound 3.39 (0.466 g, 1.72  mmol, 43%) was isolated as colourless solid. 
 
1H NMR (400 MHz, CDCl3) δH 7.15 (4H, m, H-3’, 5’), 6.86 (4H, m, H-4’, 6’), 3.83 (6H, s, 
OCH3), 2.65 (4H, t, J = 7.5 Hz, H-1’), 1.64 (4H, qr, H-2’),  
 
13C NMR (100 MHz, CDCl3) δC 157.5 (C-1), 131.3 (C-3) 129.8 (C-5), 126.7 (C-2), 120.3 
(C-4), 110.3 (C-6), 55.3 (OCH3), 30.0 (C-1’), 29.7 (C-2’). 
 
IR vmax: 2938, 2856, 1589, 1492, 1455, 1237, 1022, 735, 731 cm
-1.      
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2-(4-bromo-butyl)anisole (3.41) (0.185 g, 0.762 mmol, 19%) was isolated as colourless 
oil. 
 
1H NMR (400 MHz, CDCl3) δH 7.20 (1H, t, J = 7.5 Hz , H-3), 7.14 (1H, d, J = 8.4 Hz, H-5), 
6.89 (2H, m, H-4, 6), 3.84 (3H, s, OCH3), 3.45 (2H, t, J = 7.1 Hz, H-4’), 2.67 (2H, t, J = 
7.5 Hz, H-1’), 1.92 (2H, qr, H-3’), 1.76 (2H, qr, H-2’),  
 
13C NMR (100 MHz, CDCl3) δC 157.4 (C-1), 130.2 (C-3), 129.8 (C-5), 127.1 (C-2), 124.4 
(C-4), 110.3 (C-6), 55.2 (OCH3), 33.7 (C-3’), 32.5 (C-4’), 29.2 (C-2’), 28.3 (C-1’).  
 
IR vmax: 2935, 1599, 1492, 1239, 1031, 750 cm
-1.  
 
2,2’-Dimethoxy-biphenyl (3.42) (0.077 g, 0.361 mmol, 9.0%) was isolated as colourless 
crystals. 
 
1H NMR (400 MHz, CDCl3) δH 7.31 (2H, td, J = 8.7, 1.8 Hz, H-5), 7.28 (2H, d, J =  7.2 Hz, 
H-3), 6.98 (4H, m, H-4, 6), 3.75 (3H, s, OCH3),  
 
13C NMR (100 MHz, CDCl3) δC 157.1 (C-1), 131.4 (C-5), 128.5 (C-3), 127.9 (C-2), 120.3 
(C-4), 111.2 (C-6), 55.7 (OCH3). 
 











o-Bromoanisole (3.27) (3.00 g, 16.0 mmol) was added slowly to a mixture of Mg (0.440 g, 
18.1 mmol) turnings and 20 ml of dry THF under nitrogen. The resulting mixture was 
allowed to reflux for 2 h. The mixture was cannulated into a solution of 1,4-dibromobutane 
(3.45 g, 16.0 mmol) and 1.5 ml of 0.1 M Li2CuCl4/THF solution, stirring at 0 
oC under 
nitrogen. The reaction mixture was allowed to warm to room temperature and after 3 h 
another 1.5 ml of 0.1 M Li2CuCl4/THF was added. After 6 h, the last portion of 1.5 ml of 
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0.1 M Li2CuCl4/THF was added. After 24 h the reaction was quenched with distilled water 
(20 ml) and extracted with ethyl acetate (3 x 20 ml).  The organic layer was washed with 
dilute HCl, water and brine, dried over anhydrous MgSO4, filtered and concentrated in
vacuo.  The reaction products were purified using silica column chromatography (hexane) 
to yield compound 3.41 (2.68 g, 11.0 mmol, 69%) as a colourless oil,  
 
1H NMR (400 MHz, CDCl3) δH 7.20 (1H, t, J = 7.5 Hz , H-3), 7.14 (1H, d, J = 8.4 Hz, H-5), 
6.89 (2H, m, H-4, 6), 3.84 (3H, s, OCH3), 3.45 (2H, t, J = 7.1 Hz, H-4’), 2.67 (2H, t, J = 
7.5 Hz, H-1’), 1.92 (2H, qr, H-3’), 1.76 (2H, qr, H-2’),  
 
13C NMR (100 MHz, CDCl3) δC 157.4 (C-1), 130.2 (C-3), 129.8 (C-5), 127.1 (C-2), 124.4 
(C-4), 110.3 (C-6), 55.2 (OCH3), 33.7 (C-3’), 32.5 (C-4’), 29.2 (C-2’), 28.3 (C-1’).  
 
IR vmax: 2935, 1599, 1492, 1239, 1031, 750 cm
-1.  
 










o-Bromoanisole (3.27) (1.87 g, 10.0 mmol) was added slowly to a mixture of Mg (0.292 g, 
12.0 mmol) turnings and 20 ml of dry THF under nitrogen. The resulting mixture was 
allowed to reflux for 3h. The mixture was cannulated into a solution of 1-(4-
bromobutyl)anisole (3.41) (2.43 g, 10.0 mmol) and 1.2 ml of 0.1 M Li2CuCl4/THF 
solution, stirring at 0 oC under nitrogen. The reaction mixture was allowed to warm to 
room temperature and after 3 h another 1.2 ml of 0.1 M Li2CuCl4/THF was added. After 6 
h, the last portion of 1.2 ml of 0.1 M Li2CuCl4/THF was added. After 24 h the reaction was 
quenched with distilled water (20 ml) and extracted with ethyl acetate (3 x 20 ml).  The 
organic layer was washed with dilute HCl, water andbrine, dried over anhydrous MgSO4, 
filtered and concentrated in vacuo.  The reaction products were purified using silica 
column chromatography (hexane) to yield 3.39 (1.83 g, 6.80 mmol, 68%) as a white solid.  
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1H NMR (400 MHz, CDCl3) δH 7.15 (4H, m, H-3’, 5’), 6.86 (4H, m, H-4’, 6’), 3.83 (6H, s, 
OCH3), 2.65 (4H, t, J = 7.5 Hz, H-1’), 1.64 (4H, qr, H-2’),  
 
13C NMR (100 MHz, CDCl3) δC 157.5 (C-1), 131.3 (C-3) 129.8 (C-5), 126.7 (C-2), 120.3 
(C-4), 110.3 (C-6), 55.3 (OCH3), 30.0 (C-1’), 29.7 (C-2’). 
 
IR vmax: 2938, 2856, 1589, 1492, 1455, 1237, 1022, 735, 731 cm
-1.      
 









       
To the mixture of 10 ml dry THF and metallic lithium (0.277 g, 39.9 mmol), stirring at 0 
oC under nitrogen, was added ethylenediamine (3.68 g, 53.9 mmol). Compound 3.39 (2.00 
g, 7.40 mmol) was added and the solution was allowed to stir at 0 oC for 6 h. The 
remaining lithium was separated from the resulting deep blue solution and quenched with 
methanol. The pink reaction mixture was quenched with distilled water (15 ml) and 
extracted with diethyl ether (3 x 20 ml). The organic layer was washed with dilute HCl, 
water and brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo.  The 
reaction products were purified using silica column chromatography (1:4, diethyl ether-
hexane) to yield compound 3.40 (1.17 g, 4.81 mmol, 65%) as a whitish solid.  
 
1H NMR (400 MHz, CDCl3) δH 7.10 (4H, m, H-3, 5), 6.87 (2H, t, J = 7.6 Hz, H-4), 6.77 
(2H, d, J = 7.9 Hz, H-6), 2.68 (4H, t, J = 7.1 Hz, H-1’), 1.71 (4H, qr, H-2’),   
 
13C NMR (100 MHz, CDCl3) δC 153.4 (C-1), 130.3 (C-3), 128.4 (C-5), 127.1(C-2), 120.8 
(C-4), 115.3 (C-6), 29.5 (C-1’, 2’).  
 
IR vmax: 3487, 2938, 2856, 1587, 1500, 1448, 1168, 761, 733 cm
-1.        
 
 
